Protocol for detecting cytosol-retained proopiomelanocortin by fractionation and co-immunoprecipitation assay Authors: Sang-Hyeon Mun, Cheol-Sang Hwang Published: 2026 ABSTRACT SummarySignal peptide (SP)-uncleaved proopiomelanocortin (POMC) accumulates in the cytosol when ER translocation or protein quality control is perturbed. Here, we present a protocol to prepare and validate a POMC SP-specific antibody. We then use this antibody to detect cytosol-retained SP-uncleaved POMC in mammalian cells. We describe steps for using sequential digitonin-based semi-permeabilization followed by Triton X-100 lysis to isolate cytosolic and organelle fractions. We then detect cytosolic POMC by immunoblotting upon genetic depletion or enrich it by SP-specific immunoprecipitation.For complete details on the use and execution of this protocol, please refer to Mun et al.1 Before you begin Many eukaryotic secretory proteins can aberrantly accumulate in the cytosol as signal peptide–containing untranslocated precursors when ER translocation is disrupted, protein quality control is defective, or the signal peptide is mutated.2,3,4,5 Such cytosolic retention can exacerbate ER stress and promote cell death, contributing to proteostasis dysfunction associated with metabolic disorders and neurodegeneration.2,6 Despite the pathophysiological relevance of cytosol-accumulated secretory proteins, their detection has been technically challenging due to their limited stability and restricted subcellular accessibility. This protocol describes the generation of SP-specific POMC antibody (anti-POMCSP) and the detection of cytosol-retained SP-uncleaved proopiomelanocortin in HEK293T cells transiently expressing C-terminally HA-tagged human POMC by immunoprecipitation followed by immunoblotting. The protocol is also optimized for selective cytosolic release and can be adapted to other mammalian cell lines, including mouse hypothalamic N43/5 cells, which endogenously express POMC, as well as for endogenous protein detection under genetic depletion of relevant quality control factors, provided that digitonin concentration and incubation time are appropriately optimized. All reagents and treated cells should be prepared in advance, and freshly prepared, ice-cold buffers are required for efficient fractionation. Cell lysates and subcellular fractions must be maintained at 4°C throughout the workflow to minimize proteolytic degradation. The workflow includes the generation and validation of a signal peptide–specific antibody, same-host IgG controls, fraction-purity controls, and its application in detecting cytosol-retained C-terminally HA-tagged POMC in HEK293T cells treated with eeyarestatin I (EerI) as an ER translocon inhibitor. Innovation Previous approaches to analyzing cytosol-exposed or mislocalized secretory proteins have largely relied on indirect topology assays, in which cytosolic exposure is inferred from antibody accessibility, pulse-labeling, and sensitivity to glycosylation or enzymatic digestion under semi-permeabilized versus fully solubilized conditions.7 These approaches are useful for topology assessment but often require radiolabeling and multi-step interpretation, and they do not directly enrich SP-uncleaved precursor forms from complex lysates. This protocol advances existing biochemical approaches by combining SP-specific antibody development and validation with digitonin-based selective cytosolic release, immunoprecipitation, and immunoblotting. This workflow separates cytosolic and organelle-associated fractions, applies fraction-purity controls, and enriches the SP-retaining precursor forms from the cytosolic fraction, reducing reliance on indirect topological inference. The step-by-step format also explains how to design an SP-containing epitope, perform sequential negative and positive antibody selection for in-house antibody purification, and validate the antibody by immunoblotting and immunoprecipitation before use. The workflow is compatible with epitope-tagged constructs and, with optimization of antibody specificity and fractionation conditions, can be extended to endogenous protein detection. More broadly, this protocol can serve as a practical framework for detecting other cytosol-retained secretory precursors, from SP-specific antibody development to biochemical detection. Preparation of anti-POMC signal peptide antibody Timing: 10–11 weeks total; 9–10 weeks for step 1; 2 days for step 2; 1–3 days for step 3; 2 days for step 4 Timing: 10–11 weeks total; 9–10 weeks for step 1; 2 days for step 2; 1–3 days for step 3; 2 days for step 4 This section describes the preparation of a POMC signal peptide–specific antibody (anti-POMCSP). The workflow includes generation of rabbit polyclonal antisera, coupling of purified GST-fused POMC fragments to an affinity matrix for sequential negative and positive affinity selection to enrich signal peptide–specific antibodies, and final purification using Protein A agarose. After validation by immunoblotting and immunoprecipitation titration, the resulting anti-POMCSP antibody is used for downstream co-immunoprecipitation assay.1.Generation of crude anti-POMCSP antisera.a.Design the peptide antigen for SP-specific immunization (Figure 1A).i.Use the human POMC sequence (UniProt: P01189) to select an epitope that overlaps the signal peptide cleavage site, so that the intact contiguous epitope is retained in SP-uncleaved precursor POMC but is disrupted upon signal peptide cleavage.ii.For anti-POMCSP, use the peptide QASMEVRGWC, corresponding to residues 19–28 of human POMC, with a C-terminal cysteine included to enable carrier conjugation.Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers.Figure 1Generation and validation of Anti-POMCSP antibody(A) Schematic representation of human POMC domain and design strategy for anti-POMCSP antibody generation. The antibody epitope spans residues 19–28 within the signal peptide region, including the signal peptide cleavage site.(B) Immunoblot of GST-POMC1–76, GST-POMC1–26, and GST-POMC27–76 fusion proteins probed with anti-POMCSP. The anti-POMCSP antibody specifically recognizes proteins containing the signal peptide region (1–26). Right: CBB staining confirms equal loading of GST-fusion proteins.(C) Immunoprecipitation-based validation of anti-POMCSP antibody specificity. HEK293T cells transfected with empty vector or POMCha were treated with EerI and MG-132. Whole-cell lysates were subjected to immunoprecipitation with normal rabbit IgG or the indicated amounts of anti-POMCSP (1, 3 or 5 μg), followed by immunoblotting with anti-ha. Anti-POMCSP enriched POMCha with increasing antibody amounts, whereas normal rabbit IgG did not. Within the tested range, 5 μg anti-POMCSP provided a suitable POMCha IP signal and was selected as the working amount for subsequent CoIP assays. Tubulin serves as an input loading control.The schematic in (A) was adapted from Mun et al.1 with permission.b.Prepare a KLH-conjugated antigen.i.The synthetic peptide was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine using a heterobifunctional crosslinker (e.g., Sulfo-SMCC; Merck, M6035) by a commercial antibody service provider (AbClon, South Korea) as part of the antibody production workflow.c.Immunization.i.A typical immunization schedule includes a primary injection at week 0.ii.Booster injections at weeks 4, 6, and 8.iii.At week 9, terminal blood samples for antibody analysis against the POMC signal peptide were collected via cardiac puncture by commercial antibody service provider (AbClon, South Korea).2.Conjugate GST-POMC fragments into Affi-Gel 10/15 resins coupling.a.Prepare 1.5 mg of purified signal peptide deleted GST-POMC27–76 and 1 mg of purified GST-POMC1–76 containing signal peptide.CRITICAL: Use SP-lacking GST-POMC27–76 for negative-selection resin and SP-containing GST-POMC1–76 for positive-selection resin.b.Dialyze the purified proteins into Affi-Gel–compatible, amine-free coupling buffer at 4°C for 2 h.CRITICAL: Ensure the protein is not in buffers containing high concentrations of primary amines (e.g., Tris or glycine) during coupling, because those components can quench reactive groups on amine-reactive resins.c.Dialyze against fresh coupling buffer for an additional 4 h, then centrifuge each dialyzed protein at 12,000 × g for 10 min at 4°C to remove insoluble aggregates.Optional: If you need to generate the proteins de novo, express GST-POMC proteins in E. coli, purify using glutathione sepharose, and dialyze into a defined GST storage buffer (50 mM HEPES, 150 mM NaCl, 1 mM DTT, 10% glycerol, pH7.5) before resin coupling.d.Place a 5 mL polypropylene column on a column support stand.e.Gently swirl the Affi-Gel resin bottles to evenly resuspend the resin, then load 0.5 mL each of Affi-Gel 10 and Affi-Gel 15 (total volume, 1 mL) into the column.f.Wash and equilibrate the column with 10 mL of chilled PBS (at least five bed volumes).g.Add 1.5 mg of purified GST-POMC27–76 and 1 mg of purified GST-POMC1–76 to each column, respectively, and incubate at 4°C for 12–16 h on a rotator.Optional: To increase the efficiency of positive selection with epitope-containing proteins, increase the amount of target protein up to ∼2 mg.h.After incubation, place the column back on the stand and collect the flow-through containing unbound proteins.i.Wash the column with 5 mL of chilled PBS (at least three bed volumes).Note: After comparing protein concentrations before and after column binding, repeat the binding step with Affi-Gel 10/15 resins if necessary (steps 2h and 2i).j.Drain the PBS, add 10 mL of blocking solution (at least five bed volumes), and incubate at 20°C–25°C for 2 h on a rotator.CRITICAL: Do not allow the beads to dry completely.k.Wash the column with 10 mL of washing buffer and then with 10 mL of chilled PBS (each corresponding to at least five bed volumes).l.Cap the column, fill the column with 3 mL of PBS (at least three bed volumes) to keep the resin submerged, and store at 4°C for subsequent antibody selection.Note: Prolonged storage (>1 week) may compromise protein stability.3.Negative and positive selection of anti-POMCSP antibodies.a.Place the column conjugated with GST-POMC27–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes).b.Add 1 mL of antisera to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Antisera volume can be adjusted to 0.5–1.5 mL. Excess antisera may saturate the antigen-conjugated resin and reduce negative-selection efficiency.c.Collect the flow-through antisera and rinse the resin with a small volume (∼ up to 100 μL) of chilled PBS to ensure complete recovery of the antisera for subsequent positive selection.Optional: For resin reuse, bound antibodies can be eluted by resuspending the resin in 1 mL of elution buffer for 5 min and immediately neutralizing with 0.3 mL of 1 M Tris-HCl (pH 8.0). This process can be repeated three to four times as needed. After elution, neutralize the column with 20 mL of PBS (at least 20 bed volume).Note: Reuse of the column should be limited to a maximum of three cycles.d.Place the column conjugated with GST-POMC1–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes).e.Add 1 mL of the flow-through obtained from the negative selection (from step 3c) to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Use 0.5–1.5 mL of negative-selection flow-through for positive selection. Excess antisera may saturate the antibody-capture capacity of the GST-POMC1–76–conjugated resin, reducing selective enrichment and recovery of anti-POMCSP antibodies.f.Collect the flow-through antisera, followed by a wash of the resin with 10 mL of chilled PBS (at least 10 bed volumes).g.Elute bound antibodies by incubating the resin with 0.5 mL of elution buffer for 5 min.h.Collect the eluted fraction and immediately neutralize with 0.15 mL of 1 M Tris-HCl (pH 8.0).i.Repeat steps 3g and 3h two more times to ensure complete elution, resulting in purified antibodies in the elution fractions.4.Purification of anti-POMCSP antibodies via Protein A agarose beads (ProA).a.Place a 5 mL polypropylene column on a column support stand.b.Gently swirl the ProA-agarose resin bottle to evenly resuspend the resin, then load 0.5 mL of ProA-agarose into the column.c.Wash and equilibrate the column with 5 mL of chilled PBS (at least five bed volumes).d.Add 1.5 mL of collected antibodies (eluted in steps 3h‒3i) to the column and incubate at 4°C on a rotator for 4 h.e.After incubation, place the column back on the stand and collect the flow-through.f.Wash and equilibrate the column twice with 5 mL of chilled PBS (at least five bed volumes per wash).g.Resuspend the resin with 150 μL of elution buffer and incubate for 5 min.h.Collect the eluate, followed by immediate neutralization with 45 μL of 1 M Tris-HCl (pH 8.0).i.Repeat steps 4g and 4h two additional times to ensure complete elution.j.Dialyze the eluates against 1 L of storage buffer at 4°C for 12–16 h, followed by a second dialysis against 1 L of fresh storage buffer at 4°C for 4 h. The dialyzed product is referred to as anti-POMCSP (Figure 1B).Optional: The anti-POMCSP antibodies can be used for further analysis and stored at −20°C for short-term or at −80°C for long-term storage. 1.Generation of crude anti-POMCSP antisera.a.Design the peptide antigen for SP-specific immunization (Figure 1A).i.Use the human POMC sequence (UniProt: P01189) to select an epitope that overlaps the signal peptide cleavage site, so that the intact contiguous epitope is retained in SP-uncleaved precursor POMC but is disrupted upon signal peptide cleavage.ii.For anti-POMCSP, use the peptide QASMEVRGWC, corresponding to residues 19–28 of human POMC, with a C-terminal cysteine included to enable carrier conjugation.Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers.Figure 1Generation and validation of Anti-POMCSP antibody(A) Schematic representation of human POMC domain and design strategy for anti-POMCSP antibody generation. The antibody epitope spans residues 19–28 within the signal peptide region, including the signal peptide cleavage site.(B) Immunoblot of GST-POMC1–76, GST-POMC1–26, and GST-POMC27–76 fusion proteins probed with anti-POMCSP. The anti-POMCSP antibody specifically recognizes proteins containing the signal peptide region (1–26). Right: CBB staining confirms equal loading of GST-fusion proteins.(C) Immunoprecipitation-based validation of anti-POMCSP antibody specificity. HEK293T cells transfected with empty vector or POMCha were treated with EerI and MG-132. Whole-cell lysates were subjected to immunoprecipitation with normal rabbit IgG or the indicated amounts of anti-POMCSP (1, 3 or 5 μg), followed by immunoblotting with anti-ha. Anti-POMCSP enriched POMCha with increasing antibody amounts, whereas normal rabbit IgG did not. Within the tested range, 5 μg anti-POMCSP provided a suitable POMCha IP signal and was selected as the working amount for subsequent CoIP assays. Tubulin serves as an input loading control.The schematic in (A) was adapted from Mun et al.1 with permission.b.Prepare a KLH-conjugated antigen.i.The synthetic peptide was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine using a heterobifunctional crosslinker (e.g., Sulfo-SMCC; Merck, M6035) by a commercial antibody service provider (AbClon, South Korea) as part of the antibody production workflow.c.Immunization.i.A typical immunization schedule includes a primary injection at week 0.ii.Booster injections at weeks 4, 6, and 8.iii.At week 9, terminal blood samples for antibody analysis against the POMC signal peptide were collected via cardiac puncture by commercial antibody service provider (AbClon, South Korea). Generation of crude anti-POMCSP antisera.a.Design the peptide antigen for SP-specific immunization (Figure 1A).i.Use the human POMC sequence (UniProt: P01189) to select an epitope that overlaps the signal peptide cleavage site, so that the intact contiguous epitope is retained in SP-uncleaved precursor POMC but is disrupted upon signal peptide cleavage.ii.For anti-POMCSP, use the peptide QASMEVRGWC, corresponding to residues 19–28 of human POMC, with a C-terminal cysteine included to enable carrier conjugation.Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers.Figure 1Generation and validation of Anti-POMCSP antibody(A) Schematic representation of human POMC domain and design strategy for anti-POMCSP antibody generation. The antibody epitope spans residues 19–28 within the signal peptide region, including the signal peptide cleavage site.(B) Immunoblot of GST-POMC1–76, GST-POMC1–26, and GST-POMC27–76 fusion proteins probed with anti-POMCSP. The anti-POMCSP antibody specifically recognizes proteins containing the signal peptide region (1–26). Right: CBB staining confirms equal loading of GST-fusion proteins.(C) Immunoprecipitation-based validation of anti-POMCSP antibody specificity. HEK293T cells transfected with empty vector or POMCha were treated with EerI and MG-132. Whole-cell lysates were subjected to immunoprecipitation with normal rabbit IgG or the indicated amounts of anti-POMCSP (1, 3 or 5 μg), followed by immunoblotting with anti-ha. Anti-POMCSP enriched POMCha with increasing antibody amounts, whereas normal rabbit IgG did not. Within the tested range, 5 μg anti-POMCSP provided a suitable POMCha IP signal and was selected as the working amount for subsequent CoIP assays. Tubulin serves as an input loading control.The schematic in (A) was adapted from Mun et al.1 with permission.b.Prepare a KLH-conjugated antigen.i.The synthetic peptide was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine using a heterobifunctional crosslinker (e.g., Sulfo-SMCC; Merck, M6035) by a commercial antibody service provider (AbClon, South Korea) as part of the antibody production workflow.c.Immunization.i.A typical immunization schedule includes a primary injection at week 0.ii.Booster injections at weeks 4, 6, and 8.iii.At week 9, terminal blood samples for antibody analysis against the POMC signal peptide were collected via cardiac puncture by commercial antibody service provider (AbClon, South Korea). a.Design the peptide antigen for SP-specific immunization (Figure 1A).i.Use the human POMC sequence (UniProt: P01189) to select an epitope that overlaps the signal peptide cleavage site, so that the intact contiguous epitope is retained in SP-uncleaved precursor POMC but is disrupted upon signal peptide cleavage.ii.For anti-POMCSP, use the peptide QASMEVRGWC, corresponding to residues 19–28 of human POMC, with a C-terminal cysteine included to enable carrier conjugation.Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers.Figure 1Generation and validation of Anti-POMCSP antibody(A) Schematic representation of human POMC domain and design strategy for anti-POMCSP antibody generation. The antibody epitope spans residues 19–28 within the signal peptide region, including the signal peptide cleavage site.(B) Immunoblot of GST-POMC1–76, GST-POMC1–26, and GST-POMC27–76 fusion proteins probed with anti-POMCSP. The anti-POMCSP antibody specifically recognizes proteins containing the signal peptide region (1–26). Right: CBB staining confirms equal loading of GST-fusion proteins.(C) Immunoprecipitation-based validation of anti-POMCSP antibody specificity. HEK293T cells transfected with empty vector or POMCha were treated with EerI and MG-132. Whole-cell lysates were subjected to immunoprecipitation with normal rabbit IgG or the indicated amounts of anti-POMCSP (1, 3 or 5 μg), followed by immunoblotting with anti-ha. Anti-POMCSP enriched POMCha with increasing antibody amounts, whereas normal rabbit IgG did not. Within the tested range, 5 μg anti-POMCSP provided a suitable POMCha IP signal and was selected as the working amount for subsequent CoIP assays. Tubulin serves as an input loading control.The schematic in (A) was adapted from Mun et al.1 with permission. Design the peptide antigen for SP-specific immunization (Figure 1A).i.Use the human POMC sequence (UniProt: P01189) to select an epitope that overlaps the signal peptide cleavage site, so that the intact contiguous epitope is retained in SP-uncleaved precursor POMC but is disrupted upon signal peptide cleavage.ii.For anti-POMCSP, use the peptide QASMEVRGWC, corresponding to residues 19–28 of human POMC, with a C-terminal cysteine included to enable carrier conjugation.Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers.Figure 1Generation and validation of Anti-POMCSP antibody(A) Schematic representation of human POMC domain and design strategy for anti-POMCSP antibody generation. The antibody epitope spans residues 19–28 within the signal peptide region, including the signal peptide cleavage site.(B) Immunoblot of GST-POMC1–76, GST-POMC1–26, and GST-POMC27–76 fusion proteins probed with anti-POMCSP. The anti-POMCSP antibody specifically recognizes proteins containing the signal peptide region (1–26). Right: CBB staining confirms equal loading of GST-fusion proteins.(C) Immunoprecipitation-based validation of anti-POMCSP antibody specificity. HEK293T cells transfected with empty vector or POMCha were treated with EerI and MG-132. Whole-cell lysates were subjected to immunoprecipitation with normal rabbit IgG or the indicated amounts of anti-POMCSP (1, 3 or 5 μg), followed by immunoblotting with anti-ha. Anti-POMCSP enriched POMCha with increasing antibody amounts, whereas normal rabbit IgG did not. Within the tested range, 5 μg anti-POMCSP provided a suitable POMCha IP signal and was selected as the working amount for subsequent CoIP assays. Tubulin serves as an input loading control.The schematic in (A) was adapted from Mun et al.1 with permission. i.Use the human POMC sequence (UniProt: P01189) to select an epitope that overlaps the signal peptide cleavage site, so that the intact contiguous epitope is retained in SP-uncleaved precursor POMC but is disrupted upon signal peptide cleavage. Use the human POMC sequence (UniProt: P01189) to select an epitope that overlaps the signal peptide cleavage site, so that the intact contiguous epitope is retained in SP-uncleaved precursor POMC but is disrupted upon signal peptide cleavage. ii.For anti-POMCSP, use the peptide QASMEVRGWC, corresponding to residues 19–28 of human POMC, with a C-terminal cysteine included to enable carrier conjugation.Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers. For anti-POMCSP, use the peptide QASMEVRGWC, corresponding to residues 19–28 of human POMC, with a C-terminal cysteine included to enable carrier conjugation.Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers. Note: Small peptides are weak immunogens. Conjugate the peptide to a carrier protein (e.g., KLH, keyhole limpet hemocyanin) to enhance antigen stability and immune response.8 CRITICAL: If the selected antigenic peptide does not contain a native cysteine residue, introduce a cysteine at the C-terminus to enable efficient conjugation to KLH via thiol-reactive crosslinkers. Generation and validation of Anti-POMCSP antibody (A) Schematic representation of human POMC domain and design strategy for anti-POMCSP antibody generation. The antibody epitope spans residues 19–28 within the signal peptide region, including the signal peptide cleavage site. (B) Immunoblot of GST-POMC1–76, GST-POMC1–26, and GST-POMC27–76 fusion proteins probed with anti-POMCSP. The anti-POMCSP antibody specifically recognizes proteins containing the signal peptide region (1–26). Right: CBB staining confirms equal loading of GST-fusion proteins. (C) Immunoprecipitation-based validation of anti-POMCSP antibody specificity. HEK293T cells transfected with empty vector or POMCha were treated with EerI and MG-132. Whole-cell lysates were subjected to immunoprecipitation with normal rabbit IgG or the indicated amounts of anti-POMCSP (1, 3 or 5 μg), followed by immunoblotting with anti-ha. Anti-POMCSP enriched POMCha with increasing antibody amounts, whereas normal rabbit IgG did not. Within the tested range, 5 μg anti-POMCSP provided a suitable POMCha IP signal and was selected as the working amount for subsequent CoIP assays. Tubulin serves as an input loading control. The schematic in (A) was adapted from Mun et al.1 with permission. b.Prepare a KLH-conjugated antigen.i.The synthetic peptide was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine using a heterobifunctional crosslinker (e.g., Sulfo-SMCC; Merck, M6035) by a commercial antibody service provider (AbClon, South Korea) as part of the antibody production workflow. Prepare a KLH-conjugated antigen.i.The synthetic peptide was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine using a heterobifunctional crosslinker (e.g., Sulfo-SMCC; Merck, M6035) by a commercial antibody service provider (AbClon, South Korea) as part of the antibody production workflow. i.The synthetic peptide was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine using a heterobifunctional crosslinker (e.g., Sulfo-SMCC; Merck, M6035) by a commercial antibody service provider (AbClon, South Korea) as part of the antibody production workflow. The synthetic peptide was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine using a heterobifunctional crosslinker (e.g., Sulfo-SMCC; Merck, M6035) by a commercial antibody service provider (AbClon, South Korea) as part of the antibody production workflow. c.Immunization.i.A typical immunization schedule includes a primary injection at week 0.ii.Booster injections at weeks 4, 6, and 8.iii.At week 9, terminal blood samples for antibody analysis against the POMC signal peptide were collected via cardiac puncture by commercial antibody service provider (AbClon, South Korea). Immunization.i.A typical immunization schedule includes a primary injection at week 0.ii.Booster injections at weeks 4, 6, and 8.iii.At week 9, terminal blood samples for antibody analysis against the POMC signal peptide were collected via cardiac puncture by commercial antibody service provider (AbClon, South Korea). i.A typical immunization schedule includes a primary injection at week 0. A typical immunization schedule includes a primary injection at week 0. ii.Booster injections at weeks 4, 6, and 8. Booster injections at weeks 4, 6, and 8. iii.At week 9, terminal blood samples for antibody analysis against the POMC signal peptide were collected via cardiac puncture by commercial antibody service provider (AbClon, South Korea). At week 9, terminal blood samples for antibody analysis against the POMC signal peptide were collected via cardiac puncture by commercial antibody service provider (AbClon, South Korea). 2.Conjugate GST-POMC fragments into Affi-Gel 10/15 resins coupling.a.Prepare 1.5 mg of purified signal peptide deleted GST-POMC27–76 and 1 mg of purified GST-POMC1–76 containing signal peptide.CRITICAL: Use SP-lacking GST-POMC27–76 for negative-selection resin and SP-containing GST-POMC1–76 for positive-selection resin.b.Dialyze the purified proteins into Affi-Gel–compatible, amine-free coupling buffer at 4°C for 2 h.CRITICAL: Ensure the protein is not in buffers containing high concentrations of primary amines (e.g., Tris or glycine) during coupling, because those components can quench reactive groups on amine-reactive resins.c.Dialyze against fresh coupling buffer for an additional 4 h, then centrifuge each dialyzed protein at 12,000 × g for 10 min at 4°C to remove insoluble aggregates.Optional: If you need to generate the proteins de novo, express GST-POMC proteins in E. coli, purify using glutathione sepharose, and dialyze into a defined GST storage buffer (50 mM HEPES, 150 mM NaCl, 1 mM DTT, 10% glycerol, pH7.5) before resin coupling.d.Place a 5 mL polypropylene column on a column support stand.e.Gently swirl the Affi-Gel resin bottles to evenly resuspend the resin, then load 0.5 mL each of Affi-Gel 10 and Affi-Gel 15 (total volume, 1 mL) into the column.f.Wash and equilibrate the column with 10 mL of chilled PBS (at least five bed volumes).g.Add 1.5 mg of purified GST-POMC27–76 and 1 mg of purified GST-POMC1–76 to each column, respectively, and incubate at 4°C for 12–16 h on a rotator.Optional: To increase the efficiency of positive selection with epitope-containing proteins, increase the amount of target protein up to ∼2 mg.h.After incubation, place the column back on the stand and collect the flow-through containing unbound proteins.i.Wash the column with 5 mL of chilled PBS (at least three bed volumes).Note: After comparing protein concentrations before and after column binding, repeat the binding step with Affi-Gel 10/15 resins if necessary (steps 2h and 2i).j.Drain the PBS, add 10 mL of blocking solution (at least five bed volumes), and incubate at 20°C–25°C for 2 h on a rotator.CRITICAL: Do not allow the beads to dry completely.k.Wash the column with 10 mL of washing buffer and then with 10 mL of chilled PBS (each corresponding to at least five bed volumes).l.Cap the column, fill the column with 3 mL of PBS (at least three bed volumes) to keep the resin submerged, and store at 4°C for subsequent antibody selection.Note: Prolonged storage (>1 week) may compromise protein stability. Conjugate GST-POMC fragments into Affi-Gel 10/15 resins coupling.a.Prepare 1.5 mg of purified signal peptide deleted GST-POMC27–76 and 1 mg of purified GST-POMC1–76 containing signal peptide.CRITICAL: Use SP-lacking GST-POMC27–76 for negative-selection resin and SP-containing GST-POMC1–76 for positive-selection resin.b.Dialyze the purified proteins into Affi-Gel–compatible, amine-free coupling buffer at 4°C for 2 h.CRITICAL: Ensure the protein is not in buffers containing high concentrations of primary amines (e.g., Tris or glycine) during coupling, because those components can quench reactive groups on amine-reactive resins.c.Dialyze against fresh coupling buffer for an additional 4 h, then centrifuge each dialyzed protein at 12,000 × g for 10 min at 4°C to remove insoluble aggregates.Optional: If you need to generate the proteins de novo, express GST-POMC proteins in E. coli, purify using glutathione sepharose, and dialyze into a defined GST storage buffer (50 mM HEPES, 150 mM NaCl, 1 mM DTT, 10% glycerol, pH7.5) before resin coupling.d.Place a 5 mL polypropylene column on a column support stand.e.Gently swirl the Affi-Gel resin bottles to evenly resuspend the resin, then load 0.5 mL each of Affi-Gel 10 and Affi-Gel 15 (total volume, 1 mL) into the column.f.Wash and equilibrate the column with 10 mL of chilled PBS (at least five bed volumes).g.Add 1.5 mg of purified GST-POMC27–76 and 1 mg of purified GST-POMC1–76 to each column, respectively, and incubate at 4°C for 12–16 h on a rotator.Optional: To increase the efficiency of positive selection with epitope-containing proteins, increase the amount of target protein up to ∼2 mg.h.After incubation, place the column back on the stand and collect the flow-through containing unbound proteins.i.Wash the column with 5 mL of chilled PBS (at least three bed volumes).Note: After comparing protein concentrations before and after column binding, repeat the binding step with Affi-Gel 10/15 resins if necessary (steps 2h and 2i).j.Drain the PBS, add 10 mL of blocking solution (at least five bed volumes), and incubate at 20°C–25°C for 2 h on a rotator.CRITICAL: Do not allow the beads to dry completely.k.Wash the column with 10 mL of washing buffer and then with 10 mL of chilled PBS (each corresponding to at least five bed volumes).l.Cap the column, fill the column with 3 mL of PBS (at least three bed volumes) to keep the resin submerged, and store at 4°C for subsequent antibody selection.Note: Prolonged storage (>1 week) may compromise protein stability. a.Prepare 1.5 mg of purified signal peptide deleted GST-POMC27–76 and 1 mg of purified GST-POMC1–76 containing signal peptide.CRITICAL: Use SP-lacking GST-POMC27–76 for negative-selection resin and SP-containing GST-POMC1–76 for positive-selection resin. Prepare 1.5 mg of purified signal peptide deleted GST-POMC27–76 and 1 mg of purified GST-POMC1–76 containing signal peptide.CRITICAL: Use SP-lacking GST-POMC27–76 for negative-selection resin and SP-containing GST-POMC1–76 for positive-selection resin. CRITICAL: Use SP-lacking GST-POMC27–76 for negative-selection resin and SP-containing GST-POMC1–76 for positive-selection resin. b.Dialyze the purified proteins into Affi-Gel–compatible, amine-free coupling buffer at 4°C for 2 h.CRITICAL: Ensure the protein is not in buffers containing high concentrations of primary amines (e.g., Tris or glycine) during coupling, because those components can quench reactive groups on amine-reactive resins. Dialyze the purified proteins into Affi-Gel–compatible, amine-free coupling buffer at 4°C for 2 h.CRITICAL: Ensure the protein is not in buffers containing high concentrations of primary amines (e.g., Tris or glycine) during coupling, because those components can quench reactive groups on amine-reactive resins. CRITICAL: Ensure the protein is not in buffers containing high concentrations of primary amines (e.g., Tris or glycine) during coupling, because those components can quench reactive groups on amine-reactive resins. c.Dialyze against fresh coupling buffer for an additional 4 h, then centrifuge each dialyzed protein at 12,000 × g for 10 min at 4°C to remove insoluble aggregates.Optional: If you need to generate the proteins de novo, express GST-POMC proteins in E. coli, purify using glutathione sepharose, and dialyze into a defined GST storage buffer (50 mM HEPES, 150 mM NaCl, 1 mM DTT, 10% glycerol, pH7.5) before resin coupling. Dialyze against fresh coupling buffer for an additional 4 h, then centrifuge each dialyzed protein at 12,000 × g for 10 min at 4°C to remove insoluble aggregates.Optional: If you need to generate the proteins de novo, express GST-POMC proteins in E. coli, purify using glutathione sepharose, and dialyze into a defined GST storage buffer (50 mM HEPES, 150 mM NaCl, 1 mM DTT, 10% glycerol, pH7.5) before resin coupling. Optional: If you need to generate the proteins de novo, express GST-POMC proteins in E. coli, purify using glutathione sepharose, and dialyze into a defined GST storage buffer (50 mM HEPES, 150 mM NaCl, 1 mM DTT, 10% glycerol, pH7.5) before resin coupling. d.Place a 5 mL polypropylene column on a column support stand. Place a 5 mL polypropylene column on a column support stand. e.Gently swirl the Affi-Gel resin bottles to evenly resuspend the resin, then load 0.5 mL each of Affi-Gel 10 and Affi-Gel 15 (total volume, 1 mL) into the column. Gently swirl the Affi-Gel resin bottles to evenly resuspend the resin, then load 0.5 mL each of Affi-Gel 10 and Affi-Gel 15 (total volume, 1 mL) into the column. f.Wash and equilibrate the column with 10 mL of chilled PBS (at least five bed volumes). Wash and equilibrate the column with 10 mL of chilled PBS (at least five bed volumes). g.Add 1.5 mg of purified GST-POMC27–76 and 1 mg of purified GST-POMC1–76 to each column, respectively, and incubate at 4°C for 12–16 h on a rotator.Optional: To increase the efficiency of positive selection with epitope-containing proteins, increase the amount of target protein up to ∼2 mg. Add 1.5 mg of purified GST-POMC27–76 and 1 mg of purified GST-POMC1–76 to each column, respectively, and incubate at 4°C for 12–16 h on a rotator.Optional: To increase the efficiency of positive selection with epitope-containing proteins, increase the amount of target protein up to ∼2 mg. Optional: To increase the efficiency of positive selection with epitope-containing proteins, increase the amount of target protein up to ∼2 mg. h.After incubation, place the column back on the stand and collect the flow-through containing unbound proteins. After incubation, place the column back on the stand and collect the flow-through containing unbound proteins. i.Wash the column with 5 mL of chilled PBS (at least three bed volumes).Note: After comparing protein concentrations before and after column binding, repeat the binding step with Affi-Gel 10/15 resins if necessary (steps 2h and 2i). Wash the column with 5 mL of chilled PBS (at least three bed volumes).Note: After comparing protein concentrations before and after column binding, repeat the binding step with Affi-Gel 10/15 resins if necessary (steps 2h and 2i). Note: After comparing protein concentrations before and after column binding, repeat the binding step with Affi-Gel 10/15 resins if necessary (steps 2h and 2i). j.Drain the PBS, add 10 mL of blocking solution (at least five bed volumes), and incubate at 20°C–25°C for 2 h on a rotator.CRITICAL: Do not allow the beads to dry completely. Drain the PBS, add 10 mL of blocking solution (at least five bed volumes), and incubate at 20°C–25°C for 2 h on a rotator.CRITICAL: Do not allow the beads to dry completely. CRITICAL: Do not allow the beads to dry completely. k.Wash the column with 10 mL of washing buffer and then with 10 mL of chilled PBS (each corresponding to at least five bed volumes). Wash the column with 10 mL of washing buffer and then with 10 mL of chilled PBS (each corresponding to at least five bed volumes). l.Cap the column, fill the column with 3 mL of PBS (at least three bed volumes) to keep the resin submerged, and store at 4°C for subsequent antibody selection.Note: Prolonged storage (>1 week) may compromise protein stability. Cap the column, fill the column with 3 mL of PBS (at least three bed volumes) to keep the resin submerged, and store at 4°C for subsequent antibody selection.Note: Prolonged storage (>1 week) may compromise protein stability. Note: Prolonged storage (>1 week) may compromise protein stability. 3.Negative and positive selection of anti-POMCSP antibodies.a.Place the column conjugated with GST-POMC27–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes).b.Add 1 mL of antisera to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Antisera volume can be adjusted to 0.5–1.5 mL. Excess antisera may saturate the antigen-conjugated resin and reduce negative-selection efficiency.c.Collect the flow-through antisera and rinse the resin with a small volume (∼ up to 100 μL) of chilled PBS to ensure complete recovery of the antisera for subsequent positive selection.Optional: For resin reuse, bound antibodies can be eluted by resuspending the resin in 1 mL of elution buffer for 5 min and immediately neutralizing with 0.3 mL of 1 M Tris-HCl (pH 8.0). This process can be repeated three to four times as needed. After elution, neutralize the column with 20 mL of PBS (at least 20 bed volume).Note: Reuse of the column should be limited to a maximum of three cycles.d.Place the column conjugated with GST-POMC1–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes).e.Add 1 mL of the flow-through obtained from the negative selection (from step 3c) to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Use 0.5–1.5 mL of negative-selection flow-through for positive selection. Excess antisera may saturate the antibody-capture capacity of the GST-POMC1–76–conjugated resin, reducing selective enrichment and recovery of anti-POMCSP antibodies.f.Collect the flow-through antisera, followed by a wash of the resin with 10 mL of chilled PBS (at least 10 bed volumes).g.Elute bound antibodies by incubating the resin with 0.5 mL of elution buffer for 5 min.h.Collect the eluted fraction and immediately neutralize with 0.15 mL of 1 M Tris-HCl (pH 8.0).i.Repeat steps 3g and 3h two more times to ensure complete elution, resulting in purified antibodies in the elution fractions. Negative and positive selection of anti-POMCSP antibodies.a.Place the column conjugated with GST-POMC27–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes).b.Add 1 mL of antisera to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Antisera volume can be adjusted to 0.5–1.5 mL. Excess antisera may saturate the antigen-conjugated resin and reduce negative-selection efficiency.c.Collect the flow-through antisera and rinse the resin with a small volume (∼ up to 100 μL) of chilled PBS to ensure complete recovery of the antisera for subsequent positive selection.Optional: For resin reuse, bound antibodies can be eluted by resuspending the resin in 1 mL of elution buffer for 5 min and immediately neutralizing with 0.3 mL of 1 M Tris-HCl (pH 8.0). This process can be repeated three to four times as needed. After elution, neutralize the column with 20 mL of PBS (at least 20 bed volume).Note: Reuse of the column should be limited to a maximum of three cycles.d.Place the column conjugated with GST-POMC1–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes).e.Add 1 mL of the flow-through obtained from the negative selection (from step 3c) to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Use 0.5–1.5 mL of negative-selection flow-through for positive selection. Excess antisera may saturate the antibody-capture capacity of the GST-POMC1–76–conjugated resin, reducing selective enrichment and recovery of anti-POMCSP antibodies.f.Collect the flow-through antisera, followed by a wash of the resin with 10 mL of chilled PBS (at least 10 bed volumes).g.Elute bound antibodies by incubating the resin with 0.5 mL of elution buffer for 5 min.h.Collect the eluted fraction and immediately neutralize with 0.15 mL of 1 M Tris-HCl (pH 8.0).i.Repeat steps 3g and 3h two more times to ensure complete elution, resulting in purified antibodies in the elution fractions. a.Place the column conjugated with GST-POMC27–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes). Place the column conjugated with GST-POMC27–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes). b.Add 1 mL of antisera to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Antisera volume can be adjusted to 0.5–1.5 mL. Excess antisera may saturate the antigen-conjugated resin and reduce negative-selection efficiency. Add 1 mL of antisera to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Antisera volume can be adjusted to 0.5–1.5 mL. Excess antisera may saturate the antigen-conjugated resin and reduce negative-selection efficiency. Note: Antisera volume can be adjusted to 0.5–1.5 mL. Excess antisera may saturate the antigen-conjugated resin and reduce negative-selection efficiency. c.Collect the flow-through antisera and rinse the resin with a small volume (∼ up to 100 μL) of chilled PBS to ensure complete recovery of the antisera for subsequent positive selection.Optional: For resin reuse, bound antibodies can be eluted by resuspending the resin in 1 mL of elution buffer for 5 min and immediately neutralizing with 0.3 mL of 1 M Tris-HCl (pH 8.0). This process can be repeated three to four times as needed. After elution, neutralize the column with 20 mL of PBS (at least 20 bed volume).Note: Reuse of the column should be limited to a maximum of three cycles. Collect the flow-through antisera and rinse the resin with a small volume (∼ up to 100 μL) of chilled PBS to ensure complete recovery of the antisera for subsequent positive selection.Optional: For resin reuse, bound antibodies can be eluted by resuspending the resin in 1 mL of elution buffer for 5 min and immediately neutralizing with 0.3 mL of 1 M Tris-HCl (pH 8.0). This process can be repeated three to four times as needed. After elution, neutralize the column with 20 mL of PBS (at least 20 bed volume).Note: Reuse of the column should be limited to a maximum of three cycles. Optional: For resin reuse, bound antibodies can be eluted by resuspending the resin in 1 mL of elution buffer for 5 min and immediately neutralizing with 0.3 mL of 1 M Tris-HCl (pH 8.0). This process can be repeated three to four times as needed. After elution, neutralize the column with 20 mL of PBS (at least 20 bed volume). Note: Reuse of the column should be limited to a maximum of three cycles. d.Place the column conjugated with GST-POMC1–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes). Place the column conjugated with GST-POMC1–76 (prepared in step 2l) on the stand and wash with 5 mL of chilled PBS (at least 5 bed volumes). e.Add 1 mL of the flow-through obtained from the negative selection (from step 3c) to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Use 0.5–1.5 mL of negative-selection flow-through for positive selection. Excess antisera may saturate the antibody-capture capacity of the GST-POMC1–76–conjugated resin, reducing selective enrichment and recovery of anti-POMCSP antibodies. Add 1 mL of the flow-through obtained from the negative selection (from step 3c) to the column and incubate at 4°C on a rotator for 4–16 h (see troubleshooting 1).Note: Use 0.5–1.5 mL of negative-selection flow-through for positive selection. Excess antisera may saturate the antibody-capture capacity of the GST-POMC1–76–conjugated resin, reducing selective enrichment and recovery of anti-POMCSP antibodies. Note: Use 0.5–1.5 mL of negative-selection flow-through for positive selection. Excess antisera may saturate the antibody-capture capacity of the GST-POMC1–76–conjugated resin, reducing selective enrichment and recovery of anti-POMCSP antibodies. f.Collect the flow-through antisera, followed by a wash of the resin with 10 mL of chilled PBS (at least 10 bed volumes). Collect the flow-through antisera, followed by a wash of the resin with 10 mL of chilled PBS (at least 10 bed volumes). g.Elute bound antibodies by incubating the resin with 0.5 mL of elution buffer for 5 min. Elute bound antibodies by incubating the resin with 0.5 mL of elution buffer for 5 min. h.Collect the eluted fraction and immediately neutralize with 0.15 mL of 1 M Tris-HCl (pH 8.0). Collect the eluted fraction and immediately neutralize with 0.15 mL of 1 M Tris-HCl (pH 8.0). i.Repeat steps 3g and 3h two more times to ensure complete elution, resulting in purified antibodies in the elution fractions. Repeat steps 3g and 3h two more times to ensure complete elution, resulting in purified antibodies in the elution fractions. 4.Purification of anti-POMCSP antibodies via Protein A agarose beads (ProA).a.Place a 5 mL polypropylene column on a column support stand.b.Gently swirl the ProA-agarose resin bottle to evenly resuspend the resin, then load 0.5 mL of ProA-agarose into the column.c.Wash and equilibrate the column with 5 mL of chilled PBS (at least five bed volumes).d.Add 1.5 mL of collected antibodies (eluted in steps 3h‒3i) to the column and incubate at 4°C on a rotator for 4 h.e.After incubation, place the column back on the stand and collect the flow-through.f.Wash and equilibrate the column twice with 5 mL of chilled PBS (at least five bed volumes per wash).g.Resuspend the resin with 150 μL of elution buffer and incubate for 5 min.h.Collect the eluate, followed by immediate neutralization with 45 μL of 1 M Tris-HCl (pH 8.0).i.Repeat steps 4g and 4h two additional times to ensure complete elution.j.Dialyze the eluates against 1 L of storage buffer at 4°C for 12–16 h, followed by a second dialysis against 1 L of fresh storage buffer at 4°C for 4 h. The dialyzed product is referred to as anti-POMCSP (Figure 1B). Purification of anti-POMCSP antibodies via Protein A agarose beads (ProA).a.Place a 5 mL polypropylene column on a column support stand.b.Gently swirl the ProA-agarose resin bottle to evenly resuspend the resin, then load 0.5 mL of ProA-agarose into the column.c.Wash and equilibrate the column with 5 mL of chilled PBS (at least five bed volumes).d.Add 1.5 mL of collected antibodies (eluted in steps 3h‒3i) to the column and incubate at 4°C on a rotator for 4 h.e.After incubation, place the column back on the stand and collect the flow-through.f.Wash and equilibrate the column twice with 5 mL of chilled PBS (at least five bed volumes per wash).g.Resuspend the resin with 150 μL of elution buffer and incubate for 5 min.h.Collect the eluate, followed by immediate neutralization with 45 μL of 1 M Tris-HCl (pH 8.0).i.Repeat steps 4g and 4h two additional times to ensure complete elution.j.Dialyze the eluates against 1 L of storage buffer at 4°C for 12–16 h, followed by a second dialysis against 1 L of fresh storage buffer at 4°C for 4 h. The dialyzed product is referred to as anti-POMCSP (Figure 1B). a.Place a 5 mL polypropylene column on a column support stand. Place a 5 mL polypropylene column on a column support stand. b.Gently swirl the ProA-agarose resin bottle to evenly resuspend the resin, then load 0.5 mL of ProA-agarose into the column. Gently swirl the ProA-agarose resin bottle to evenly resuspend the resin, then load 0.5 mL of ProA-agarose into the column. c.Wash and equilibrate the column with 5 mL of chilled PBS (at least five bed volumes). Wash and equilibrate the column with 5 mL of chilled PBS (at least five bed volumes). d.Add 1.5 mL of collected antibodies (eluted in steps 3h‒3i) to the column and incubate at 4°C on a rotator for 4 h. Add 1.5 mL of collected antibodies (eluted in steps 3h‒3i) to the column and incubate at 4°C on a rotator for 4 h. e.After incubation, place the column back on the stand and collect the flow-through. After incubation, place the column back on the stand and collect the flow-through. f.Wash and equilibrate the column twice with 5 mL of chilled PBS (at least five bed volumes per wash). Wash and equilibrate the column twice with 5 mL of chilled PBS (at least five bed volumes per wash). g.Resuspend the resin with 150 μL of elution buffer and incubate for 5 min. Resuspend the resin with 150 μL of elution buffer and incubate for 5 min. h.Collect the eluate, followed by immediate neutralization with 45 μL of 1 M Tris-HCl (pH 8.0). Collect the eluate, followed by immediate neutralization with 45 μL of 1 M Tris-HCl (pH 8.0). i.Repeat steps 4g and 4h two additional times to ensure complete elution. Repeat steps 4g and 4h two additional times to ensure complete elution. j.Dialyze the eluates against 1 L of storage buffer at 4°C for 12–16 h, followed by a second dialysis against 1 L of fresh storage buffer at 4°C for 4 h. The dialyzed product is referred to as anti-POMCSP (Figure 1B). Dialyze the eluates against 1 L of storage buffer at 4°C for 12–16 h, followed by a second dialysis against 1 L of fresh storage buffer at 4°C for 4 h. The dialyzed product is referred to as anti-POMCSP (Figure 1B). Optional: The anti-POMCSP antibodies can be used for further analysis and stored at −20°C for short-term or at −80°C for long-term storage. Preparation of N43/5 and HEK293T cells Timing: 3–4 days total; 1 day for step 5; 2–3 days for step 6 Timing: 3–4 days total; 1 day for step 5; 2–3 days for step 6 As MARCHF6 targets cytosol-retained POMC for degradation,1 Marchf6-KO N43/5 mouse hypothalamic cells are used to detect endogenous cytosolic POMC. Prepare one 10-cm dish per experimental condition for cytosol–organelle fractionation. Both cytosolic and organelle fractions are obtained sequentially from the same dish. Cells are grown in 10-cm dishes and harvested at 80–90% confluence, followed by immediate lysis for downstream analyses. The following cell culture procedure applies to both N43/5 and HEK293T cells.5.Cell thawing and recovery.a.Immediately thaw a frozen cell vial in a 37°C water bath for 1‒2 min until completely thawed.CRITICAL: Do not overexpose the vial to 37°C during thawing.b.Transfer the cell suspension to 5 mL of pre-warmed culture medium (DMEM supplemented with 10% of fetal bovine serum and 1% penicillin/streptomycin for N43/5 and HEK293T cells) in a 15 mL conical tube.CRITICAL: Pre-warm the culture medium to 37°C before use to minimize temperature-induced stress. Handle thawed cells gently during transfer to avoid mechanical damage.c.Centrifuge at 250 × g for 3 min to pellet the cells.d.Discard the supernatant.e.Gently resuspend the cell pellet in 2 mL of culture medium by pipetting up and down.f.Transfer the cell suspension to a 10-cm cell culture dish containing 8 mL of pre-warmed culture medium.g.Incubate at 37°C in a humidified incubator with 5% CO2.h.After 24 h of incubation, check cell morphology under a microscope and replace the medium with 10 mL of fresh pre-warmed culture medium.i.Continue incubation until cells reach about 80%–90% confluence.6.Subculture and seed N43/5 cells.a.When cells reach 80%–90% confluence, remove the medium and wash once with 3 mL of pre-warmed PBS.CRITICAL: Avoid the usage of chilled PBS during routine passaging. Add PBS slowly along the wall of the culture dish to prevent detachment of adherent cells.b.Carefully aspirate PBS.c.Add 1.5 mL of 0.25% Trypsin-EDTA solution to the 10-cm dish. Gently rock the dish to completely cover the cell monolayer.d.Place the 10-cm cell culture dish in a 37°C incubator with 5% CO2 for 1‒2 min.CRITICAL: Limit the Trypsin-EDTA exposure to no longer than 3 min to prevent cell damage.e.Gently tap the sides of the 10-cm dish to facilitate detachment.f.Add 8 mL of pre-warmed culture medium to neutralize the trypsin.g.Carefully pipette the cell suspension across the surface of the 10-cm dish to collect all detached cells.h.Transfer the suspension to a 15 mL conical tube.i.Centrifuge at 250 × g for 3 min to pellet the cells.j.Discard the supernatant.k.Resuspend the cell pellet in 10 mL of pre-warmed culture medium.l.Determine cell number using an automated cell counter (CellDrop FL).m.Seed 1.5 × 106 wild-type and Marchf6-KO N43/5 cells per 10-cm cell culture dish. Add culture medium to a final volume of 10 mL per dish.Note: For each fractionation experiment, prepare one 10-cm dish per genotype.n.Gently swirl the 10-cm dish to distribute cells evenly, then place it in a 37°C incubator with 5% CO2.o.Incubate until cells reach 80%–90% confluence (approximately 24–36 h), then harvest the cells. 5.Cell thawing and recovery.a.Immediately thaw a frozen cell vial in a 37°C water bath for 1‒2 min until completely thawed.CRITICAL: Do not overexpose the vial to 37°C during thawing.b.Transfer the cell suspension to 5 mL of pre-warmed culture medium (DMEM supplemented with 10% of fetal bovine serum and 1% penicillin/streptomycin for N43/5 and HEK293T cells) in a 15 mL conical tube.CRITICAL: Pre-warm the culture medium to 37°C before use to minimize temperature-induced stress. Handle thawed cells gently during transfer to avoid mechanical damage.c.Centrifuge at 250 × g for 3 min to pellet the cells.d.Discard the supernatant.e.Gently resuspend the cell pellet in 2 mL of culture medium by pipetting up and down.f.Transfer the cell suspension to a 10-cm cell culture dish containing 8 mL of pre-warmed culture medium.g.Incubate at 37°C in a humidified incubator with 5% CO2.h.After 24 h of incubation, check cell morphology under a microscope and replace the medium with 10 mL of fresh pre-warmed culture medium.i.Continue incubation until cells reach about 80%–90% confluence. Cell thawing and recovery.a.Immediately thaw a frozen cell vial in a 37°C water bath for 1‒2 min until completely thawed.CRITICAL: Do not overexpose the vial to 37°C during thawing.b.Transfer the cell suspension to 5 mL of pre-warmed culture medium (DMEM supplemented with 10% of fetal bovine serum and 1% penicillin/streptomycin for N43/5 and HEK293T cells) in a 15 mL conical tube.CRITICAL: Pre-warm the culture medium to 37°C before use to minimize temperature-induced stress. Handle thawed cells gently during transfer to avoid mechanical damage.c.Centrifuge at 250 × g for 3 min to pellet the cells.d.Discard the supernatant.e.Gently resuspend the cell pellet in 2 mL of culture medium by pipetting up and down.f.Transfer the cell suspension to a 10-cm cell culture dish containing 8 mL of pre-warmed culture medium.g.Incubate at 37°C in a humidified incubator with 5% CO2.h.After 24 h of incubation, check cell morphology under a microscope and replace the medium with 10 mL of fresh pre-warmed culture medium.i.Continue incubation until cells reach about 80%–90% confluence. a.Immediately thaw a frozen cell vial in a 37°C water bath for 1‒2 min until completely thawed.CRITICAL: Do not overexpose the vial to 37°C during thawing. Immediately thaw a frozen cell vial in a 37°C water bath for 1‒2 min until completely thawed.CRITICAL: Do not overexpose the vial to 37°C during thawing. CRITICAL: Do not overexpose the vial to 37°C during thawing. b.Transfer the cell suspension to 5 mL of pre-warmed culture medium (DMEM supplemented with 10% of fetal bovine serum and 1% penicillin/streptomycin for N43/5 and HEK293T cells) in a 15 mL conical tube.CRITICAL: Pre-warm the culture medium to 37°C before use to minimize temperature-induced stress. Handle thawed cells gently during transfer to avoid mechanical damage. Transfer the cell suspension to 5 mL of pre-warmed culture medium (DMEM supplemented with 10% of fetal bovine serum and 1% penicillin/streptomycin for N43/5 and HEK293T cells) in a 15 mL conical tube.CRITICAL: Pre-warm the culture medium to 37°C before use to minimize temperature-induced stress. Handle thawed cells gently during transfer to avoid mechanical damage. CRITICAL: Pre-warm the culture medium to 37°C before use to minimize temperature-induced stress. Handle thawed cells gently during transfer to avoid mechanical damage. c.Centrifuge at 250 × g for 3 min to pellet the cells. Centrifuge at 250 × g for 3 min to pellet the cells. d.Discard the supernatant. Discard the supernatant. e.Gently resuspend the cell pellet in 2 mL of culture medium by pipetting up and down. Gently resuspend the cell pellet in 2 mL of culture medium by pipetting up and down. f.Transfer the cell suspension to a 10-cm cell culture dish containing 8 mL of pre-warmed culture medium. Transfer the cell suspension to a 10-cm cell culture dish containing 8 mL of pre-warmed culture medium. g.Incubate at 37°C in a humidified incubator with 5% CO2. Incubate at 37°C in a humidified incubator with 5% CO2. h.After 24 h of incubation, check cell morphology under a microscope and replace the medium with 10 mL of fresh pre-warmed culture medium. After 24 h of incubation, check cell morphology under a microscope and replace the medium with 10 mL of fresh pre-warmed culture medium. i.Continue incubation until cells reach about 80%–90% confluence. Continue incubation until cells reach about 80%–90% confluence. 6.Subculture and seed N43/5 cells.a.When cells reach 80%–90% confluence, remove the medium and wash once with 3 mL of pre-warmed PBS.CRITICAL: Avoid the usage of chilled PBS during routine passaging. Add PBS slowly along the wall of the culture dish to prevent detachment of adherent cells.b.Carefully aspirate PBS.c.Add 1.5 mL of 0.25% Trypsin-EDTA solution to the 10-cm dish. Gently rock the dish to completely cover the cell monolayer.d.Place the 10-cm cell culture dish in a 37°C incubator with 5% CO2 for 1‒2 min.CRITICAL: Limit the Trypsin-EDTA exposure to no longer than 3 min to prevent cell damage.e.Gently tap the sides of the 10-cm dish to facilitate detachment.f.Add 8 mL of pre-warmed culture medium to neutralize the trypsin.g.Carefully pipette the cell suspension across the surface of the 10-cm dish to collect all detached cells.h.Transfer the suspension to a 15 mL conical tube.i.Centrifuge at 250 × g for 3 min to pellet the cells.j.Discard the supernatant.k.Resuspend the cell pellet in 10 mL of pre-warmed culture medium.l.Determine cell number using an automated cell counter (CellDrop FL).m.Seed 1.5 × 106 wild-type and Marchf6-KO N43/5 cells per 10-cm cell culture dish. Add culture medium to a final volume of 10 mL per dish.Note: For each fractionation experiment, prepare one 10-cm dish per genotype.n.Gently swirl the 10-cm dish to distribute cells evenly, then place it in a 37°C incubator with 5% CO2.o.Incubate until cells reach 80%–90% confluence (approximately 24–36 h), then harvest the cells. Subculture and seed N43/5 cells.a.When cells reach 80%–90% confluence, remove the medium and wash once with 3 mL of pre-warmed PBS.CRITICAL: Avoid the usage of chilled PBS during routine passaging. Add PBS slowly along the wall of the culture dish to prevent detachment of adherent cells.b.Carefully aspirate PBS.c.Add 1.5 mL of 0.25% Trypsin-EDTA solution to the 10-cm dish. Gently rock the dish to completely cover the cell monolayer.d.Place the 10-cm cell culture dish in a 37°C incubator with 5% CO2 for 1‒2 min.CRITICAL: Limit the Trypsin-EDTA exposure to no longer than 3 min to prevent cell damage.e.Gently tap the sides of the 10-cm dish to facilitate detachment.f.Add 8 mL of pre-warmed culture medium to neutralize the trypsin.g.Carefully pipette the cell suspension across the surface of the 10-cm dish to collect all detached cells.h.Transfer the suspension to a 15 mL conical tube.i.Centrifuge at 250 × g for 3 min to pellet the cells.j.Discard the supernatant.k.Resuspend the cell pellet in 10 mL of pre-warmed culture medium.l.Determine cell number using an automated cell counter (CellDrop FL).m.Seed 1.5 × 106 wild-type and Marchf6-KO N43/5 cells per 10-cm cell culture dish. Add culture medium to a final volume of 10 mL per dish.Note: For each fractionation experiment, prepare one 10-cm dish per genotype.n.Gently swirl the 10-cm dish to distribute cells evenly, then place it in a 37°C incubator with 5% CO2.o.Incubate until cells reach 80%–90% confluence (approximately 24–36 h), then harvest the cells. a.When cells reach 80%–90% confluence, remove the medium and wash once with 3 mL of pre-warmed PBS.CRITICAL: Avoid the usage of chilled PBS during routine passaging. Add PBS slowly along the wall of the culture dish to prevent detachment of adherent cells. When cells reach 80%–90% confluence, remove the medium and wash once with 3 mL of pre-warmed PBS.CRITICAL: Avoid the usage of chilled PBS during routine passaging. Add PBS slowly along the wall of the culture dish to prevent detachment of adherent cells. CRITICAL: Avoid the usage of chilled PBS during routine passaging. Add PBS slowly along the wall of the culture dish to prevent detachment of adherent cells. b.Carefully aspirate PBS. Carefully aspirate PBS. c.Add 1.5 mL of 0.25% Trypsin-EDTA solution to the 10-cm dish. Gently rock the dish to completely cover the cell monolayer. Add 1.5 mL of 0.25% Trypsin-EDTA solution to the 10-cm dish. Gently rock the dish to completely cover the cell monolayer. d.Place the 10-cm cell culture dish in a 37°C incubator with 5% CO2 for 1‒2 min.CRITICAL: Limit the Trypsin-EDTA exposure to no longer than 3 min to prevent cell damage. Place the 10-cm cell culture dish in a 37°C incubator with 5% CO2 for 1‒2 min.CRITICAL: Limit the Trypsin-EDTA exposure to no longer than 3 min to prevent cell damage. CRITICAL: Limit the Trypsin-EDTA exposure to no longer than 3 min to prevent cell damage. e.Gently tap the sides of the 10-cm dish to facilitate detachment. Gently tap the sides of the 10-cm dish to facilitate detachment. f.Add 8 mL of pre-warmed culture medium to neutralize the trypsin. Add 8 mL of pre-warmed culture medium to neutralize the trypsin. g.Carefully pipette the cell suspension across the surface of the 10-cm dish to collect all detached cells. Carefully pipette the cell suspension across the surface of the 10-cm dish to collect all detached cells. h.Transfer the suspension to a 15 mL conical tube. Transfer the suspension to a 15 mL conical tube. i.Centrifuge at 250 × g for 3 min to pellet the cells. Centrifuge at 250 × g for 3 min to pellet the cells. j.Discard the supernatant. Discard the supernatant. k.Resuspend the cell pellet in 10 mL of pre-warmed culture medium. Resuspend the cell pellet in 10 mL of pre-warmed culture medium. l.Determine cell number using an automated cell counter (CellDrop FL). Determine cell number using an automated cell counter (CellDrop FL). m.Seed 1.5 × 106 wild-type and Marchf6-KO N43/5 cells per 10-cm cell culture dish. Add culture medium to a final volume of 10 mL per dish.Note: For each fractionation experiment, prepare one 10-cm dish per genotype. Seed 1.5 × 106 wild-type and Marchf6-KO N43/5 cells per 10-cm cell culture dish. Add culture medium to a final volume of 10 mL per dish.Note: For each fractionation experiment, prepare one 10-cm dish per genotype. Note: For each fractionation experiment, prepare one 10-cm dish per genotype. n.Gently swirl the 10-cm dish to distribute cells evenly, then place it in a 37°C incubator with 5% CO2. Gently swirl the 10-cm dish to distribute cells evenly, then place it in a 37°C incubator with 5% CO2. o.Incubate until cells reach 80%–90% confluence (approximately 24–36 h), then harvest the cells. Incubate until cells reach 80%–90% confluence (approximately 24–36 h), then harvest the cells. Preparation of HEK293T cells treated with EerI Timing: 4–5 days Timing: 4–5 days This section describes the transient expression of POMCha in HEK293T cells. MG-132 is used to stabilize rapidly degraded cytosolic proteins, and EerI inhibits ER translocation to promote cytosolic accumulation of SP-uncleaved POMC. HEK293T cells were thawed and subcultured as described in steps 5 and 6a–6h prior to transfection.7.POMCha plasmid DNA transfection in HEK293T cells.a.Seed 3.5 × 106 HEK293T cells per 10-cm dish 16–24 h before transfection to achieve 60%–70% confluence at the time of transfection.Note: Use one 10-cm dish per condition for downstream fractionation and co-IP experiment.b.Approximately 16–24 h after seeding, transfect cells with 5 μg of POMCha plasmid DNA using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) according to the manufacturer’s instructions with pre-warmed Opti-MEM (see troubleshooting 2 and 3).Note: Use a 1:3 DNA (μg) to Lipofectamine 2000 (μL) ratio for HEK293T cells.c.Carefully add the DNA–Lipofectamine 2000 complexes dropwise to the cells and gently swirl 10-cm dish to distribute evenly.d.Incubate the cells for 16–24 h at 37°C in a humidified 5% CO2 incubator.e.Replace the medium with 10 mL of the fresh pre-warmed culture medium.f.Incubate the cells for an additional 24–36 h at 37°C in a humidified 5% CO2 incubator to allow robust POMCha expression.g.Treat the cells with 8 μM EerI or vehicle control in the presence of 10 μM of MG-132 for 8 h. 7.POMCha plasmid DNA transfection in HEK293T cells.a.Seed 3.5 × 106 HEK293T cells per 10-cm dish 16–24 h before transfection to achieve 60%–70% confluence at the time of transfection.Note: Use one 10-cm dish per condition for downstream fractionation and co-IP experiment.b.Approximately 16–24 h after seeding, transfect cells with 5 μg of POMCha plasmid DNA using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) according to the manufacturer’s instructions with pre-warmed Opti-MEM (see troubleshooting 2 and 3).Note: Use a 1:3 DNA (μg) to Lipofectamine 2000 (μL) ratio for HEK293T cells.c.Carefully add the DNA–Lipofectamine 2000 complexes dropwise to the cells and gently swirl 10-cm dish to distribute evenly.d.Incubate the cells for 16–24 h at 37°C in a humidified 5% CO2 incubator.e.Replace the medium with 10 mL of the fresh pre-warmed culture medium.f.Incubate the cells for an additional 24–36 h at 37°C in a humidified 5% CO2 incubator to allow robust POMCha expression.g.Treat the cells with 8 μM EerI or vehicle control in the presence of 10 μM of MG-132 for 8 h. POMCha plasmid DNA transfection in HEK293T cells.a.Seed 3.5 × 106 HEK293T cells per 10-cm dish 16–24 h before transfection to achieve 60%–70% confluence at the time of transfection.Note: Use one 10-cm dish per condition for downstream fractionation and co-IP experiment.b.Approximately 16–24 h after seeding, transfect cells with 5 μg of POMCha plasmid DNA using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) according to the manufacturer’s instructions with pre-warmed Opti-MEM (see troubleshooting 2 and 3).Note: Use a 1:3 DNA (μg) to Lipofectamine 2000 (μL) ratio for HEK293T cells.c.Carefully add the DNA–Lipofectamine 2000 complexes dropwise to the cells and gently swirl 10-cm dish to distribute evenly.d.Incubate the cells for 16–24 h at 37°C in a humidified 5% CO2 incubator.e.Replace the medium with 10 mL of the fresh pre-warmed culture medium.f.Incubate the cells for an additional 24–36 h at 37°C in a humidified 5% CO2 incubator to allow robust POMCha expression.g.Treat the cells with 8 μM EerI or vehicle control in the presence of 10 μM of MG-132 for 8 h. a.Seed 3.5 × 106 HEK293T cells per 10-cm dish 16–24 h before transfection to achieve 60%–70% confluence at the time of transfection.Note: Use one 10-cm dish per condition for downstream fractionation and co-IP experiment. Seed 3.5 × 106 HEK293T cells per 10-cm dish 16–24 h before transfection to achieve 60%–70% confluence at the time of transfection.Note: Use one 10-cm dish per condition for downstream fractionation and co-IP experiment. Note: Use one 10-cm dish per condition for downstream fractionation and co-IP experiment. b.Approximately 16–24 h after seeding, transfect cells with 5 μg of POMCha plasmid DNA using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) according to the manufacturer’s instructions with pre-warmed Opti-MEM (see troubleshooting 2 and 3).Note: Use a 1:3 DNA (μg) to Lipofectamine 2000 (μL) ratio for HEK293T cells. Approximately 16–24 h after seeding, transfect cells with 5 μg of POMCha plasmid DNA using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) according to the manufacturer’s instructions with pre-warmed Opti-MEM (see troubleshooting 2 and 3).Note: Use a 1:3 DNA (μg) to Lipofectamine 2000 (μL) ratio for HEK293T cells. Note: Use a 1:3 DNA (μg) to Lipofectamine 2000 (μL) ratio for HEK293T cells. c.Carefully add the DNA–Lipofectamine 2000 complexes dropwise to the cells and gently swirl 10-cm dish to distribute evenly. Carefully add the DNA–Lipofectamine 2000 complexes dropwise to the cells and gently swirl 10-cm dish to distribute evenly. d.Incubate the cells for 16–24 h at 37°C in a humidified 5% CO2 incubator. Incubate the cells for 16–24 h at 37°C in a humidified 5% CO2 incubator. e.Replace the medium with 10 mL of the fresh pre-warmed culture medium. Replace the medium with 10 mL of the fresh pre-warmed culture medium. f.Incubate the cells for an additional 24–36 h at 37°C in a humidified 5% CO2 incubator to allow robust POMCha expression. Incubate the cells for an additional 24–36 h at 37°C in a humidified 5% CO2 incubator to allow robust POMCha expression. g.Treat the cells with 8 μM EerI or vehicle control in the presence of 10 μM of MG-132 for 8 h. Treat the cells with 8 μM EerI or vehicle control in the presence of 10 μM of MG-132 for 8 h. Harvest cells for subcellular fractionation Timing: 1–2 h Timing: 1–2 h This section describes harvesting of N43/5 (step 6) and HEK293T cells (step 7) for subcellular fractionation. Harvest one 10-cm dish per condition. Before starting, pre-chill all reagents, tubes, and the centrifuge to 4°C.8.Harvest N43/5 and HEK293T cells.a.Remove the medium and wash once with 5 mL of ice-cold PBS in a 10-cm dish.b.Scrape the cells in ice-cold PBS using a cell scraper and transfer the suspension to a pre-chilled 15 mL conical tube (see troubleshooting 4).CRITICAL: Perform this step on ice or at 4°C to minimize proteolysis.c.Centrifuge at 500 × g for 5 min at 4°C to pellet the cells.d.Carefully remove the supernatant and gently resuspend the pellet in 1 mL of ice-cold PBS.e.Transfer to a pre-chilled 1.5 mL microcentrifuge tube.f.Reserve 100 μL (10% of the total volume) as the whole-cell lysate (input) and keep on ice.g.Centrifuge both the input and the remaining suspension at 500 × g for 5 min at 4°C.h.Remove the supernatant. The cell pellet is ready for subcellular fractionation.CRITICAL: Proceed immediately to subcellular extraction. Do not freeze or store cell pellets prior to digitonin extraction, as this may increase organelle leakage and reduce reproducibility. 8.Harvest N43/5 and HEK293T cells.a.Remove the medium and wash once with 5 mL of ice-cold PBS in a 10-cm dish.b.Scrape the cells in ice-cold PBS using a cell scraper and transfer the suspension to a pre-chilled 15 mL conical tube (see troubleshooting 4).CRITICAL: Perform this step on ice or at 4°C to minimize proteolysis.c.Centrifuge at 500 × g for 5 min at 4°C to pellet the cells.d.Carefully remove the supernatant and gently resuspend the pellet in 1 mL of ice-cold PBS.e.Transfer to a pre-chilled 1.5 mL microcentrifuge tube.f.Reserve 100 μL (10% of the total volume) as the whole-cell lysate (input) and keep on ice.g.Centrifuge both the input and the remaining suspension at 500 × g for 5 min at 4°C.h.Remove the supernatant. The cell pellet is ready for subcellular fractionation.CRITICAL: Proceed immediately to subcellular extraction. Do not freeze or store cell pellets prior to digitonin extraction, as this may increase organelle leakage and reduce reproducibility. Harvest N43/5 and HEK293T cells.a.Remove the medium and wash once with 5 mL of ice-cold PBS in a 10-cm dish.b.Scrape the cells in ice-cold PBS using a cell scraper and transfer the suspension to a pre-chilled 15 mL conical tube (see troubleshooting 4).CRITICAL: Perform this step on ice or at 4°C to minimize proteolysis.c.Centrifuge at 500 × g for 5 min at 4°C to pellet the cells.d.Carefully remove the supernatant and gently resuspend the pellet in 1 mL of ice-cold PBS.e.Transfer to a pre-chilled 1.5 mL microcentrifuge tube.f.Reserve 100 μL (10% of the total volume) as the whole-cell lysate (input) and keep on ice.g.Centrifuge both the input and the remaining suspension at 500 × g for 5 min at 4°C.h.Remove the supernatant. The cell pellet is ready for subcellular fractionation.CRITICAL: Proceed immediately to subcellular extraction. Do not freeze or store cell pellets prior to digitonin extraction, as this may increase organelle leakage and reduce reproducibility. a.Remove the medium and wash once with 5 mL of ice-cold PBS in a 10-cm dish. Remove the medium and wash once with 5 mL of ice-cold PBS in a 10-cm dish. b.Scrape the cells in ice-cold PBS using a cell scraper and transfer the suspension to a pre-chilled 15 mL conical tube (see troubleshooting 4).CRITICAL: Perform this step on ice or at 4°C to minimize proteolysis. Scrape the cells in ice-cold PBS using a cell scraper and transfer the suspension to a pre-chilled 15 mL conical tube (see troubleshooting 4).CRITICAL: Perform this step on ice or at 4°C to minimize proteolysis. CRITICAL: Perform this step on ice or at 4°C to minimize proteolysis. c.Centrifuge at 500 × g for 5 min at 4°C to pellet the cells. Centrifuge at 500 × g for 5 min at 4°C to pellet the cells. d.Carefully remove the supernatant and gently resuspend the pellet in 1 mL of ice-cold PBS. Carefully remove the supernatant and gently resuspend the pellet in 1 mL of ice-cold PBS. e.Transfer to a pre-chilled 1.5 mL microcentrifuge tube. Transfer to a pre-chilled 1.5 mL microcentrifuge tube. f.Reserve 100 μL (10% of the total volume) as the whole-cell lysate (input) and keep on ice. Reserve 100 μL (10% of the total volume) as the whole-cell lysate (input) and keep on ice. g.Centrifuge both the input and the remaining suspension at 500 × g for 5 min at 4°C. Centrifuge both the input and the remaining suspension at 500 × g for 5 min at 4°C. h.Remove the supernatant. The cell pellet is ready for subcellular fractionation.CRITICAL: Proceed immediately to subcellular extraction. Do not freeze or store cell pellets prior to digitonin extraction, as this may increase organelle leakage and reduce reproducibility. Remove the supernatant. The cell pellet is ready for subcellular fractionation.CRITICAL: Proceed immediately to subcellular extraction. Do not freeze or store cell pellets prior to digitonin extraction, as this may increase organelle leakage and reduce reproducibility. CRITICAL: Proceed immediately to subcellular extraction. Do not freeze or store cell pellets prior to digitonin extraction, as this may increase organelle leakage and reduce reproducibility. Qualification of anti-POMCSP antibody Timing: 3–5 days total; 1–2 days for step 9; 2–3 days for step 10 Timing: 3–5 days total; 1–2 days for step 9; 2–3 days for step 10 This step validates the specificity and functionality of purified anti-POMCSP antibody prior to its use in downstream co-immunoprecipitation experiments. First, the antibody is tested against recombinant GST-POMC fragments to confirm signal peptide-dependent recognition. Next, its performance is evaluated by cell-based immunoprecipitation using whole-cell lysates from POMCha-expressing HEK293T.9.Validation of anti-POMCSP specificity by immunoblotting.a.Prepare GST-POMC1–26, GST-POMC1–76, and signal peptide-deleted GST-POMC27–76 samples (1 μg per lane) by mixing with 4× SDS sample buffer to a final 1× concentration, then heat at 95°C for 5 min.Note: Prepare duplicate gels for Coomassie Brilliant Blue (CBB) staining to confirm equal loading.b.Separate the recombinant proteins on 10% SDS-PAGE gels at a constant 80 V for 2.5 h.c.Transfer proteins from one gel to a PVDF membrane and immunoblot with anti-POMCSP antibody (as detailed in step 10f).d.Stain the duplicate gel with CBB staining to confirm equal loading.10.Validation of anti-POMCSP performance for immunoprecipitation.a.Preparation of HEK293T cell samples.i.Prepare two 10-cm dishes of HEK293T cells transfected with empty vector and four 10-cm dishes of HEK293T cells expressing POMCha (as described in step 7).ii.Treat all dishes with 8 μM EerI and 10 μM MG-132 for 8 h.iii.Harvest the cells (as described in step 8).b.Preparation of whole-cell lysates and input samples.i.Lyse each cell pellet in 1 mL of ice-cold RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Incubate for 20 min on ice with occasional gentle mixing.iii.Centrifuge at 13,500 × g for 15 min at 4°C.iv.Transfer the supernatant to a pre-chilled microcentrifuge tube as the cleared whole-cell lysate.v.Measure the protein concentration of each lysate using a BCA protein assay kit.Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1.Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5vi.Reserve 10 μg of each lysate as the input sample.vii.Mix each input sample with 4× SDS sample buffer to a final 1× concentration and heat at 95°C for 5 min.Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis.c.Incubation of lysates with normal rabbit IgG or anti-POMCSP antibody.i.Normalize 1 mg of each cleared lysate to a final volume of 1 mL using RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Add the indicated amount of normal rabbit IgG or anti-POMCSP to each sample according to the immunoprecipitation conditions listed in Table 1.iii.Incubate the lysates on an orbital rotator for 12–16 h at 4°C.d.Preparation of Dynabeads Protein G.i.Gently resuspend Dynabeads Protein G, then transfer 120 μg (∼4 μL) of beads per sample into a pre-chilled microcentrifuge tube.ii.Add 0.5 mL of RIPA buffer supplemented with 1× protease inhibitor cocktail to the beads and equilibrate the beads for 5–10 min at 4°C with rotation.iii.Place the tube on a magnetic rack and discard the supernatant.iv.Repeat steps 10dii and 10diii once more.e.Immunoprecipitation of SP-uncleaved POMCha.i.Add the antibody-incubated lysate (from Step 10c) directly to the washed Dynabeads Protein G and incubate on an orbital rotator for 1.5 h at 4°C.ii.Place the tube on a magnetic rack and carefully aspirate the supernatant.iii.Wash the beads with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation.iv.Return the tube to the magnetic rack and carefully discard the supernatant.v.Repeat steps 10eiii and 10eiv two additional times.vi.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.vii.Mix thoroughly and heat at 95°C for 5 min.viii.Place the tube on the magnetic rack and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis.f.Detection of SP-uncleaved POMCha by immunoblotting.i.Load 10 μg of each input sample and 5 μL of each IP sample onto 10% SDS-PAGE gels and separate proteins at a constant 80 V for 2.5 h.ii.Transfer proteins onto a PVDF membrane at 180 mA for 2.5 h at 4°C.iii.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.iv.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12‒16 h at 4°C with gentle shaking.Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C.Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000v.Wash the membranes three times with PBS-T for 10 min each time on a shaker.vi.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C on a shaker.vii.Wash the membranes three times with PBS-T for 5 min each time on a shaker.viii.Develop the membranes using a chemiluminescent substrate and acquire images using an imaging system (Amersham Imager 680). 9.Validation of anti-POMCSP specificity by immunoblotting.a.Prepare GST-POMC1–26, GST-POMC1–76, and signal peptide-deleted GST-POMC27–76 samples (1 μg per lane) by mixing with 4× SDS sample buffer to a final 1× concentration, then heat at 95°C for 5 min.Note: Prepare duplicate gels for Coomassie Brilliant Blue (CBB) staining to confirm equal loading.b.Separate the recombinant proteins on 10% SDS-PAGE gels at a constant 80 V for 2.5 h.c.Transfer proteins from one gel to a PVDF membrane and immunoblot with anti-POMCSP antibody (as detailed in step 10f).d.Stain the duplicate gel with CBB staining to confirm equal loading. Validation of anti-POMCSP specificity by immunoblotting.a.Prepare GST-POMC1–26, GST-POMC1–76, and signal peptide-deleted GST-POMC27–76 samples (1 μg per lane) by mixing with 4× SDS sample buffer to a final 1× concentration, then heat at 95°C for 5 min.Note: Prepare duplicate gels for Coomassie Brilliant Blue (CBB) staining to confirm equal loading.b.Separate the recombinant proteins on 10% SDS-PAGE gels at a constant 80 V for 2.5 h.c.Transfer proteins from one gel to a PVDF membrane and immunoblot with anti-POMCSP antibody (as detailed in step 10f).d.Stain the duplicate gel with CBB staining to confirm equal loading. a.Prepare GST-POMC1–26, GST-POMC1–76, and signal peptide-deleted GST-POMC27–76 samples (1 μg per lane) by mixing with 4× SDS sample buffer to a final 1× concentration, then heat at 95°C for 5 min.Note: Prepare duplicate gels for Coomassie Brilliant Blue (CBB) staining to confirm equal loading. Prepare GST-POMC1–26, GST-POMC1–76, and signal peptide-deleted GST-POMC27–76 samples (1 μg per lane) by mixing with 4× SDS sample buffer to a final 1× concentration, then heat at 95°C for 5 min.Note: Prepare duplicate gels for Coomassie Brilliant Blue (CBB) staining to confirm equal loading. Note: Prepare duplicate gels for Coomassie Brilliant Blue (CBB) staining to confirm equal loading. b.Separate the recombinant proteins on 10% SDS-PAGE gels at a constant 80 V for 2.5 h. Separate the recombinant proteins on 10% SDS-PAGE gels at a constant 80 V for 2.5 h. c.Transfer proteins from one gel to a PVDF membrane and immunoblot with anti-POMCSP antibody (as detailed in step 10f). Transfer proteins from one gel to a PVDF membrane and immunoblot with anti-POMCSP antibody (as detailed in step 10f). d.Stain the duplicate gel with CBB staining to confirm equal loading. Stain the duplicate gel with CBB staining to confirm equal loading. 10.Validation of anti-POMCSP performance for immunoprecipitation.a.Preparation of HEK293T cell samples.i.Prepare two 10-cm dishes of HEK293T cells transfected with empty vector and four 10-cm dishes of HEK293T cells expressing POMCha (as described in step 7).ii.Treat all dishes with 8 μM EerI and 10 μM MG-132 for 8 h.iii.Harvest the cells (as described in step 8).b.Preparation of whole-cell lysates and input samples.i.Lyse each cell pellet in 1 mL of ice-cold RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Incubate for 20 min on ice with occasional gentle mixing.iii.Centrifuge at 13,500 × g for 15 min at 4°C.iv.Transfer the supernatant to a pre-chilled microcentrifuge tube as the cleared whole-cell lysate.v.Measure the protein concentration of each lysate using a BCA protein assay kit.Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1.Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5vi.Reserve 10 μg of each lysate as the input sample.vii.Mix each input sample with 4× SDS sample buffer to a final 1× concentration and heat at 95°C for 5 min.Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis.c.Incubation of lysates with normal rabbit IgG or anti-POMCSP antibody.i.Normalize 1 mg of each cleared lysate to a final volume of 1 mL using RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Add the indicated amount of normal rabbit IgG or anti-POMCSP to each sample according to the immunoprecipitation conditions listed in Table 1.iii.Incubate the lysates on an orbital rotator for 12–16 h at 4°C.d.Preparation of Dynabeads Protein G.i.Gently resuspend Dynabeads Protein G, then transfer 120 μg (∼4 μL) of beads per sample into a pre-chilled microcentrifuge tube.ii.Add 0.5 mL of RIPA buffer supplemented with 1× protease inhibitor cocktail to the beads and equilibrate the beads for 5–10 min at 4°C with rotation.iii.Place the tube on a magnetic rack and discard the supernatant.iv.Repeat steps 10dii and 10diii once more.e.Immunoprecipitation of SP-uncleaved POMCha.i.Add the antibody-incubated lysate (from Step 10c) directly to the washed Dynabeads Protein G and incubate on an orbital rotator for 1.5 h at 4°C.ii.Place the tube on a magnetic rack and carefully aspirate the supernatant.iii.Wash the beads with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation.iv.Return the tube to the magnetic rack and carefully discard the supernatant.v.Repeat steps 10eiii and 10eiv two additional times.vi.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.vii.Mix thoroughly and heat at 95°C for 5 min.viii.Place the tube on the magnetic rack and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis.f.Detection of SP-uncleaved POMCha by immunoblotting.i.Load 10 μg of each input sample and 5 μL of each IP sample onto 10% SDS-PAGE gels and separate proteins at a constant 80 V for 2.5 h.ii.Transfer proteins onto a PVDF membrane at 180 mA for 2.5 h at 4°C.iii.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.iv.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12‒16 h at 4°C with gentle shaking.Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C.Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000v.Wash the membranes three times with PBS-T for 10 min each time on a shaker.vi.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C on a shaker.vii.Wash the membranes three times with PBS-T for 5 min each time on a shaker.viii.Develop the membranes using a chemiluminescent substrate and acquire images using an imaging system (Amersham Imager 680). Validation of anti-POMCSP performance for immunoprecipitation.a.Preparation of HEK293T cell samples.i.Prepare two 10-cm dishes of HEK293T cells transfected with empty vector and four 10-cm dishes of HEK293T cells expressing POMCha (as described in step 7).ii.Treat all dishes with 8 μM EerI and 10 μM MG-132 for 8 h.iii.Harvest the cells (as described in step 8).b.Preparation of whole-cell lysates and input samples.i.Lyse each cell pellet in 1 mL of ice-cold RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Incubate for 20 min on ice with occasional gentle mixing.iii.Centrifuge at 13,500 × g for 15 min at 4°C.iv.Transfer the supernatant to a pre-chilled microcentrifuge tube as the cleared whole-cell lysate.v.Measure the protein concentration of each lysate using a BCA protein assay kit.Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1.Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5vi.Reserve 10 μg of each lysate as the input sample.vii.Mix each input sample with 4× SDS sample buffer to a final 1× concentration and heat at 95°C for 5 min.Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis.c.Incubation of lysates with normal rabbit IgG or anti-POMCSP antibody.i.Normalize 1 mg of each cleared lysate to a final volume of 1 mL using RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Add the indicated amount of normal rabbit IgG or anti-POMCSP to each sample according to the immunoprecipitation conditions listed in Table 1.iii.Incubate the lysates on an orbital rotator for 12–16 h at 4°C.d.Preparation of Dynabeads Protein G.i.Gently resuspend Dynabeads Protein G, then transfer 120 μg (∼4 μL) of beads per sample into a pre-chilled microcentrifuge tube.ii.Add 0.5 mL of RIPA buffer supplemented with 1× protease inhibitor cocktail to the beads and equilibrate the beads for 5–10 min at 4°C with rotation.iii.Place the tube on a magnetic rack and discard the supernatant.iv.Repeat steps 10dii and 10diii once more.e.Immunoprecipitation of SP-uncleaved POMCha.i.Add the antibody-incubated lysate (from Step 10c) directly to the washed Dynabeads Protein G and incubate on an orbital rotator for 1.5 h at 4°C.ii.Place the tube on a magnetic rack and carefully aspirate the supernatant.iii.Wash the beads with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation.iv.Return the tube to the magnetic rack and carefully discard the supernatant.v.Repeat steps 10eiii and 10eiv two additional times.vi.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.vii.Mix thoroughly and heat at 95°C for 5 min.viii.Place the tube on the magnetic rack and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis.f.Detection of SP-uncleaved POMCha by immunoblotting.i.Load 10 μg of each input sample and 5 μL of each IP sample onto 10% SDS-PAGE gels and separate proteins at a constant 80 V for 2.5 h.ii.Transfer proteins onto a PVDF membrane at 180 mA for 2.5 h at 4°C.iii.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.iv.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12‒16 h at 4°C with gentle shaking.Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C.Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000v.Wash the membranes three times with PBS-T for 10 min each time on a shaker.vi.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C on a shaker.vii.Wash the membranes three times with PBS-T for 5 min each time on a shaker.viii.Develop the membranes using a chemiluminescent substrate and acquire images using an imaging system (Amersham Imager 680). a.Preparation of HEK293T cell samples.i.Prepare two 10-cm dishes of HEK293T cells transfected with empty vector and four 10-cm dishes of HEK293T cells expressing POMCha (as described in step 7).ii.Treat all dishes with 8 μM EerI and 10 μM MG-132 for 8 h.iii.Harvest the cells (as described in step 8). Preparation of HEK293T cell samples.i.Prepare two 10-cm dishes of HEK293T cells transfected with empty vector and four 10-cm dishes of HEK293T cells expressing POMCha (as described in step 7).ii.Treat all dishes with 8 μM EerI and 10 μM MG-132 for 8 h.iii.Harvest the cells (as described in step 8). i.Prepare two 10-cm dishes of HEK293T cells transfected with empty vector and four 10-cm dishes of HEK293T cells expressing POMCha (as described in step 7). Prepare two 10-cm dishes of HEK293T cells transfected with empty vector and four 10-cm dishes of HEK293T cells expressing POMCha (as described in step 7). ii.Treat all dishes with 8 μM EerI and 10 μM MG-132 for 8 h. Treat all dishes with 8 μM EerI and 10 μM MG-132 for 8 h. iii.Harvest the cells (as described in step 8). Harvest the cells (as described in step 8). b.Preparation of whole-cell lysates and input samples.i.Lyse each cell pellet in 1 mL of ice-cold RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Incubate for 20 min on ice with occasional gentle mixing.iii.Centrifuge at 13,500 × g for 15 min at 4°C.iv.Transfer the supernatant to a pre-chilled microcentrifuge tube as the cleared whole-cell lysate.v.Measure the protein concentration of each lysate using a BCA protein assay kit.Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1.Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5vi.Reserve 10 μg of each lysate as the input sample.vii.Mix each input sample with 4× SDS sample buffer to a final 1× concentration and heat at 95°C for 5 min.Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis. Preparation of whole-cell lysates and input samples.i.Lyse each cell pellet in 1 mL of ice-cold RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Incubate for 20 min on ice with occasional gentle mixing.iii.Centrifuge at 13,500 × g for 15 min at 4°C.iv.Transfer the supernatant to a pre-chilled microcentrifuge tube as the cleared whole-cell lysate.v.Measure the protein concentration of each lysate using a BCA protein assay kit.Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1.Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5vi.Reserve 10 μg of each lysate as the input sample.vii.Mix each input sample with 4× SDS sample buffer to a final 1× concentration and heat at 95°C for 5 min.Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis. i.Lyse each cell pellet in 1 mL of ice-cold RIPA buffer supplemented with 1× protease inhibitor cocktail. Lyse each cell pellet in 1 mL of ice-cold RIPA buffer supplemented with 1× protease inhibitor cocktail. ii.Incubate for 20 min on ice with occasional gentle mixing. Incubate for 20 min on ice with occasional gentle mixing. iii.Centrifuge at 13,500 × g for 15 min at 4°C. Centrifuge at 13,500 × g for 15 min at 4°C. iv.Transfer the supernatant to a pre-chilled microcentrifuge tube as the cleared whole-cell lysate. Transfer the supernatant to a pre-chilled microcentrifuge tube as the cleared whole-cell lysate. v.Measure the protein concentration of each lysate using a BCA protein assay kit.Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1.Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5 Measure the protein concentration of each lysate using a BCA protein assay kit.Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1.Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5 Note: Pool cleared lysates from the same transfection and treatment condition if necessary to obtain sufficient protein for all immunoprecipitation conditions listed in Table 1. Table 1Immunoprecipitation conditions for anti-POMCSP validationIP laneTransfected plasmidAntibody for IPAntibody amount (μg)1pcDNA3.1(+)Normal rabbit IgG52pcDNA3.1-POMChaNormal rabbit IgG53pcDNA3.1(+)Rabbit anti-POMCSP54pcDNA3.1-POMChaRabbit anti-POMCSP15pcDNA3.1-POMChaRabbit anti-POMCSP36pcDNA3.1-POMChaRabbit anti-POMCSP5 Immunoprecipitation conditions for anti-POMCSP validation vi.Reserve 10 μg of each lysate as the input sample. Reserve 10 μg of each lysate as the input sample. vii.Mix each input sample with 4× SDS sample buffer to a final 1× concentration and heat at 95°C for 5 min.Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis. Mix each input sample with 4× SDS sample buffer to a final 1× concentration and heat at 95°C for 5 min.Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis. Pause point: Input samples can be stored at −20°C until SDS-PAGE analysis. c.Incubation of lysates with normal rabbit IgG or anti-POMCSP antibody.i.Normalize 1 mg of each cleared lysate to a final volume of 1 mL using RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Add the indicated amount of normal rabbit IgG or anti-POMCSP to each sample according to the immunoprecipitation conditions listed in Table 1.iii.Incubate the lysates on an orbital rotator for 12–16 h at 4°C. Incubation of lysates with normal rabbit IgG or anti-POMCSP antibody.i.Normalize 1 mg of each cleared lysate to a final volume of 1 mL using RIPA buffer supplemented with 1× protease inhibitor cocktail.ii.Add the indicated amount of normal rabbit IgG or anti-POMCSP to each sample according to the immunoprecipitation conditions listed in Table 1.iii.Incubate the lysates on an orbital rotator for 12–16 h at 4°C. i.Normalize 1 mg of each cleared lysate to a final volume of 1 mL using RIPA buffer supplemented with 1× protease inhibitor cocktail. Normalize 1 mg of each cleared lysate to a final volume of 1 mL using RIPA buffer supplemented with 1× protease inhibitor cocktail. ii.Add the indicated amount of normal rabbit IgG or anti-POMCSP to each sample according to the immunoprecipitation conditions listed in Table 1. Add the indicated amount of normal rabbit IgG or anti-POMCSP to each sample according to the immunoprecipitation conditions listed in Table 1. iii.Incubate the lysates on an orbital rotator for 12–16 h at 4°C. Incubate the lysates on an orbital rotator for 12–16 h at 4°C. d.Preparation of Dynabeads Protein G.i.Gently resuspend Dynabeads Protein G, then transfer 120 μg (∼4 μL) of beads per sample into a pre-chilled microcentrifuge tube.ii.Add 0.5 mL of RIPA buffer supplemented with 1× protease inhibitor cocktail to the beads and equilibrate the beads for 5–10 min at 4°C with rotation.iii.Place the tube on a magnetic rack and discard the supernatant.iv.Repeat steps 10dii and 10diii once more. Preparation of Dynabeads Protein G.i.Gently resuspend Dynabeads Protein G, then transfer 120 μg (∼4 μL) of beads per sample into a pre-chilled microcentrifuge tube.ii.Add 0.5 mL of RIPA buffer supplemented with 1× protease inhibitor cocktail to the beads and equilibrate the beads for 5–10 min at 4°C with rotation.iii.Place the tube on a magnetic rack and discard the supernatant.iv.Repeat steps 10dii and 10diii once more. i.Gently resuspend Dynabeads Protein G, then transfer 120 μg (∼4 μL) of beads per sample into a pre-chilled microcentrifuge tube. Gently resuspend Dynabeads Protein G, then transfer 120 μg (∼4 μL) of beads per sample into a pre-chilled microcentrifuge tube. ii.Add 0.5 mL of RIPA buffer supplemented with 1× protease inhibitor cocktail to the beads and equilibrate the beads for 5–10 min at 4°C with rotation. Add 0.5 mL of RIPA buffer supplemented with 1× protease inhibitor cocktail to the beads and equilibrate the beads for 5–10 min at 4°C with rotation. iii.Place the tube on a magnetic rack and discard the supernatant. Place the tube on a magnetic rack and discard the supernatant. iv.Repeat steps 10dii and 10diii once more. Repeat steps 10dii and 10diii once more. e.Immunoprecipitation of SP-uncleaved POMCha.i.Add the antibody-incubated lysate (from Step 10c) directly to the washed Dynabeads Protein G and incubate on an orbital rotator for 1.5 h at 4°C.ii.Place the tube on a magnetic rack and carefully aspirate the supernatant.iii.Wash the beads with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation.iv.Return the tube to the magnetic rack and carefully discard the supernatant.v.Repeat steps 10eiii and 10eiv two additional times.vi.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.vii.Mix thoroughly and heat at 95°C for 5 min.viii.Place the tube on the magnetic rack and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis. Immunoprecipitation of SP-uncleaved POMCha.i.Add the antibody-incubated lysate (from Step 10c) directly to the washed Dynabeads Protein G and incubate on an orbital rotator for 1.5 h at 4°C.ii.Place the tube on a magnetic rack and carefully aspirate the supernatant.iii.Wash the beads with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation.iv.Return the tube to the magnetic rack and carefully discard the supernatant.v.Repeat steps 10eiii and 10eiv two additional times.vi.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.vii.Mix thoroughly and heat at 95°C for 5 min.viii.Place the tube on the magnetic rack and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis. i.Add the antibody-incubated lysate (from Step 10c) directly to the washed Dynabeads Protein G and incubate on an orbital rotator for 1.5 h at 4°C. Add the antibody-incubated lysate (from Step 10c) directly to the washed Dynabeads Protein G and incubate on an orbital rotator for 1.5 h at 4°C. ii.Place the tube on a magnetic rack and carefully aspirate the supernatant. Place the tube on a magnetic rack and carefully aspirate the supernatant. iii.Wash the beads with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation. Wash the beads with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation. iv.Return the tube to the magnetic rack and carefully discard the supernatant. Return the tube to the magnetic rack and carefully discard the supernatant. v.Repeat steps 10eiii and 10eiv two additional times. Repeat steps 10eiii and 10eiv two additional times. vi.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample. After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample. vii.Mix thoroughly and heat at 95°C for 5 min. Mix thoroughly and heat at 95°C for 5 min. viii.Place the tube on the magnetic rack and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis. Place the tube on the magnetic rack and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis. Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis. f.Detection of SP-uncleaved POMCha by immunoblotting.i.Load 10 μg of each input sample and 5 μL of each IP sample onto 10% SDS-PAGE gels and separate proteins at a constant 80 V for 2.5 h.ii.Transfer proteins onto a PVDF membrane at 180 mA for 2.5 h at 4°C.iii.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.iv.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12‒16 h at 4°C with gentle shaking.Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C.Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000v.Wash the membranes three times with PBS-T for 10 min each time on a shaker.vi.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C on a shaker.vii.Wash the membranes three times with PBS-T for 5 min each time on a shaker.viii.Develop the membranes using a chemiluminescent substrate and acquire images using an imaging system (Amersham Imager 680). Detection of SP-uncleaved POMCha by immunoblotting.i.Load 10 μg of each input sample and 5 μL of each IP sample onto 10% SDS-PAGE gels and separate proteins at a constant 80 V for 2.5 h.ii.Transfer proteins onto a PVDF membrane at 180 mA for 2.5 h at 4°C.iii.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.iv.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12‒16 h at 4°C with gentle shaking.Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C.Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000v.Wash the membranes three times with PBS-T for 10 min each time on a shaker.vi.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C on a shaker.vii.Wash the membranes three times with PBS-T for 5 min each time on a shaker.viii.Develop the membranes using a chemiluminescent substrate and acquire images using an imaging system (Amersham Imager 680). i.Load 10 μg of each input sample and 5 μL of each IP sample onto 10% SDS-PAGE gels and separate proteins at a constant 80 V for 2.5 h. Load 10 μg of each input sample and 5 μL of each IP sample onto 10% SDS-PAGE gels and separate proteins at a constant 80 V for 2.5 h. ii.Transfer proteins onto a PVDF membrane at 180 mA for 2.5 h at 4°C. Transfer proteins onto a PVDF membrane at 180 mA for 2.5 h at 4°C. iii.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking. Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking. iv.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12‒16 h at 4°C with gentle shaking.Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C.Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000 Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12‒16 h at 4°C with gentle shaking.Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C.Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000 Note: The membranes can alternatively be incubated with primary antibody for 1–3 h at 20°C–25°C. Table 2Dilutions of antibodies for immunoblottingAntibodyDilutionGoat anti-POMC1:1,500Mouse anti-ha1:2,000Mouse anti-α-tubulin1:2,000Rabbit anti-Calreticulin1:1,000Rabbit anti-POMCSP1:500Rabbit anti-Sec61A11:1,000Goat anti-mouse IgG HRP conjugate1:5,000Goat anti-rabbit IgG HRP conjugate1:5,000Rabbit anti-goat IgG HRP conjugate1:5,000 Dilutions of antibodies for immunoblotting v.Wash the membranes three times with PBS-T for 10 min each time on a shaker. Wash the membranes three times with PBS-T for 10 min each time on a shaker. vi.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C on a shaker. Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C on a shaker. vii.Wash the membranes three times with PBS-T for 5 min each time on a shaker. Wash the membranes three times with PBS-T for 5 min each time on a shaker. viii.Develop the membranes using a chemiluminescent substrate and acquire images using an imaging system (Amersham Imager 680). Develop the membranes using a chemiluminescent substrate and acquire images using an imaging system (Amersham Imager 680). Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesGoat anti-mouse IgG (H+L) HRP conjugate (IB: 1:5,000)Bio-RadCat# 170-6516, RRID:AB_11125547Goat anti-rabbit IgG (H+L) HRP conjugate (IB: 1:5,000)Bio-RadCat# 170-6515, RRID:AB_11125142Goat anti-POMC (IB: 1:1,500)NovusCat# NB 100-1533, RRID:AB_526344Mouse anti-ha (Clone HA-7) (IB: 1:2,000)Sigma-AldrichCat# H9658, RRID:AB_260092Mouse anti-α-tubulin (IB: 1:2,000)Sigma-AldrichCat# T5168, RRID:AB_477579Rabbit anti-Calreticulin (IB: 1:1,000)AbcamCat# ab92516, RRID:AB_10562796Rabbit normal anti-IgG (IP: 5 μg per 1 mg lysate)Cell Signaling TechnologyCat# 2729, RRID:AB_1031062Rabbit anti-Sec61A1 (D7Q6V) (IB 1:1,000)Cell Signaling TechnologyCat# 14868, RRID:AB_2722736Rabbit anti-POMCSP (IB: 1:500; IP 5 μg per 1 mg lysate)Mun et al.1N/ARabbit anti-goat IgG (H+L) HRP conjugate (1:5,000)R&D SystemsCat# HAF017, RRID:AB_562588Bacterial and virus strainsBL21(DE3)Lab collectionN/ADH5αLab collectionN/AChemicals, peptides, and recombinant proteins1,4-Dithiothreitol (DTT)Bio BasicDB0058; CAS: 27565-41-93-color Broad Range Protein MarkerSMOBIOPM2700Affi-gel 10/15 combinationBio-Rad1536098Benzamidine hydrochlorideSigma-Aldrich434760; CAS: 1670-14-0Bromophenol BlueSigma-Aldrich114391; 115-39-9Clarity western ECL substrateBio-Rad1705061Clarity Max western ECL substrateBio-Rad1705062cOmplete™, EDTA-free Protease Inhibitor CocktailRoche4693132001DigitoninCalbiochem300410; CAS: 11024-24-1Dimethyl sulfoxide (DMSO)Sigma-AldrichD2650; CAS: 67-68-5Dulbecco’s modified Eagle’s medium (DMEM)CytivaSH30243.01Dynabeads protein GThermo Fisher Scientific10004DEthylenediaminetetraacetic acid (EDTA)Daejung4000-4400; CAS: 60-00-4Eeyarestatin I (EerI)Sigma-AldrichE1286; CAS: 412960-54-4Fetal bovine serum (FBS)HyCloneSH30919.03GlycerolJunsei27210S0350; CAS: 56-81-5GlycineJunsei27185S0350; CAS: 56-40-6GST-POMC1–76Mun et al.1N/AGST-POMC1–26Mun et al.1N/AGST-POMC27–76Mun et al.1N/AHEPESSigma-AldrichH3375; CAS: 7365-45-9KOAcJunsei31090S1250; CAS: 127-08-2Lipofectamine 2000Thermo Fisher Scientific11668019MG-132Merck474790; CAS: 133407-82-6Magnesium chloride hexahydrateSigma-AldrichM2393; CAS: 7791-18-6RIPA lysis bufferThermo Fisher Scientific89900Sodium dodecyl sulfate (SDS)Bio-Rad1610302; CAS: 151-21-3Sodium chlorideLPS SolutionNACL01; CAS: 7647-14-5Sodium azideBiobasicDB0613; CAS: 26628-22-8Sulfo-SMCCSigma-AldrichM6035; CAS: 92921-24-9Nonidet P40 substituteSigma-Aldrich11754599001; CAS: 9016-45-9Opti-MEM reduced-serum mediumGibco31985062Penicillin/streptomycinHyCloneSV30010Phenylmethanesulfonyl fluoride solution (PMSF)Sigma-Aldrich93482; CAS: 329-98-6Phosphate buffered saline (PBS)Lonza17-516QPOMCSP peptide antigen (QASMEVRGWC)Mun et al.1N/AProtein A (ProA) agaroseAmicogen1010005PVDF membraneSigma-AldrichIPVH00010Triton X-100Sigma-AldrichX100; CAS: 9036-19-5TrisLPS SolutionTRI01; CAS: 77-86-1TrypsinHyCloneSH30042.01Critical commercial assaysBCA protein assay kitThermo Fisher Scientific23227Experimental models: Cell linesHEK293TATCCCRL-3216N43/5Cellutions Biosystems Inc.CLU127Marchf6-KO N43/5Mun et al.1N/ARecombinant DNApCH60 (pcDNA3.1(+))Lab collectionN/ApCH4129 (pcDNA3.1-POMCha)Mun et al.1N/AOther5 mL polypropylene columnsThermo Fisher Scientific2992210-cm cell culture dishSPL20100Amersham Imager 680GE Healthcare29270769Cell culture incubatorEppendorfC170CellDrop Automated Cell CountersDenovixCellDrop FLCell scraperSPL90020 REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesGoat anti-mouse IgG (H+L) HRP conjugate (IB: 1:5,000)Bio-RadCat# 170-6516, RRID:AB_11125547Goat anti-rabbit IgG (H+L) HRP conjugate (IB: 1:5,000)Bio-RadCat# 170-6515, RRID:AB_11125142Goat anti-POMC (IB: 1:1,500)NovusCat# NB 100-1533, RRID:AB_526344Mouse anti-ha (Clone HA-7) (IB: 1:2,000)Sigma-AldrichCat# H9658, RRID:AB_260092Mouse anti-α-tubulin (IB: 1:2,000)Sigma-AldrichCat# T5168, RRID:AB_477579Rabbit anti-Calreticulin (IB: 1:1,000)AbcamCat# ab92516, RRID:AB_10562796Rabbit normal anti-IgG (IP: 5 μg per 1 mg lysate)Cell Signaling TechnologyCat# 2729, RRID:AB_1031062Rabbit anti-Sec61A1 (D7Q6V) (IB 1:1,000)Cell Signaling TechnologyCat# 14868, RRID:AB_2722736Rabbit anti-POMCSP (IB: 1:500; IP 5 μg per 1 mg lysate)Mun et al.1N/ARabbit anti-goat IgG (H+L) HRP conjugate (1:5,000)R&D SystemsCat# HAF017, RRID:AB_562588Bacterial and virus strainsBL21(DE3)Lab collectionN/ADH5αLab collectionN/AChemicals, peptides, and recombinant proteins1,4-Dithiothreitol (DTT)Bio BasicDB0058; CAS: 27565-41-93-color Broad Range Protein MarkerSMOBIOPM2700Affi-gel 10/15 combinationBio-Rad1536098Benzamidine hydrochlorideSigma-Aldrich434760; CAS: 1670-14-0Bromophenol BlueSigma-Aldrich114391; 115-39-9Clarity western ECL substrateBio-Rad1705061Clarity Max western ECL substrateBio-Rad1705062cOmplete™, EDTA-free Protease Inhibitor CocktailRoche4693132001DigitoninCalbiochem300410; CAS: 11024-24-1Dimethyl sulfoxide (DMSO)Sigma-AldrichD2650; CAS: 67-68-5Dulbecco’s modified Eagle’s medium (DMEM)CytivaSH30243.01Dynabeads protein GThermo Fisher Scientific10004DEthylenediaminetetraacetic acid (EDTA)Daejung4000-4400; CAS: 60-00-4Eeyarestatin I (EerI)Sigma-AldrichE1286; CAS: 412960-54-4Fetal bovine serum (FBS)HyCloneSH30919.03GlycerolJunsei27210S0350; CAS: 56-81-5GlycineJunsei27185S0350; CAS: 56-40-6GST-POMC1–76Mun et al.1N/AGST-POMC1–26Mun et al.1N/AGST-POMC27–76Mun et al.1N/AHEPESSigma-AldrichH3375; CAS: 7365-45-9KOAcJunsei31090S1250; CAS: 127-08-2Lipofectamine 2000Thermo Fisher Scientific11668019MG-132Merck474790; CAS: 133407-82-6Magnesium chloride hexahydrateSigma-AldrichM2393; CAS: 7791-18-6RIPA lysis bufferThermo Fisher Scientific89900Sodium dodecyl sulfate (SDS)Bio-Rad1610302; CAS: 151-21-3Sodium chlorideLPS SolutionNACL01; CAS: 7647-14-5Sodium azideBiobasicDB0613; CAS: 26628-22-8Sulfo-SMCCSigma-AldrichM6035; CAS: 92921-24-9Nonidet P40 substituteSigma-Aldrich11754599001; CAS: 9016-45-9Opti-MEM reduced-serum mediumGibco31985062Penicillin/streptomycinHyCloneSV30010Phenylmethanesulfonyl fluoride solution (PMSF)Sigma-Aldrich93482; CAS: 329-98-6Phosphate buffered saline (PBS)Lonza17-516QPOMCSP peptide antigen (QASMEVRGWC)Mun et al.1N/AProtein A (ProA) agaroseAmicogen1010005PVDF membraneSigma-AldrichIPVH00010Triton X-100Sigma-AldrichX100; CAS: 9036-19-5TrisLPS SolutionTRI01; CAS: 77-86-1TrypsinHyCloneSH30042.01Critical commercial assaysBCA protein assay kitThermo Fisher Scientific23227Experimental models: Cell linesHEK293TATCCCRL-3216N43/5Cellutions Biosystems Inc.CLU127Marchf6-KO N43/5Mun et al.1N/ARecombinant DNApCH60 (pcDNA3.1(+))Lab collectionN/ApCH4129 (pcDNA3.1-POMCha)Mun et al.1N/AOther5 mL polypropylene columnsThermo Fisher Scientific2992210-cm cell culture dishSPL20100Amersham Imager 680GE Healthcare29270769Cell culture incubatorEppendorfC170CellDrop Automated Cell CountersDenovixCellDrop FLCell scraperSPL90020 Materials and equipment Reagents for cell culture DMEM culture medium (for culturing N43/5 and HEK293T cells)ReagentFinal concentrationAmountDMEMN/A445 mLFetal bovine serum (FBS)10 %50 mLPenicillin/streptomycin (100×)1×5 mLTotalN/A500 mLStore at 4°C for up to 2 months. DMEM culture medium (for culturing N43/5 and HEK293T cells)ReagentFinal concentrationAmountDMEMN/A445 mLFetal bovine serum (FBS)10 %50 mLPenicillin/streptomycin (100×)1×5 mLTotalN/A500 mLStore at 4°C for up to 2 months. DMEM culture medium (for culturing N43/5 and HEK293T cells) Store at 4°C for up to 2 months. Reagents for antibody purification Coupling bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.5)20 mM40 mL2 M NaCl solution100 mM100 mL10 % NP-40 solution0.05 %10 mL1 M DTT solution1 mM2 mL0.5 M EDTA solution0.5 mM2 mLGlycerol10 %200 mL0.1 M PMSF solution0.1 mM2 mLddH2ON/Aup to 2LTotalN/A2 LPrepare the buffer just before. Keep at 4°C during use and discard after the experiment. Blocking bufferReagentFinal concentrationAmountTris1 M6.057 gddH2ON/Aup to 50 mLTotalN/A50 mLAdjust pH to 7.6. Store at 4°C for up to 2 months. Washing solutionReagentFinal concentrationAmount2 M NaCl solution1 M50 mLddH2ON/Aup to 100 mLTotalN/A100 mLStore at 20°C–25°C for up to 6 months. Elution solutionReagentFinal concentrationAmountGlycine0.1 M0.375 gddH2ON/Aup to 50 mLTotalN/A50 mLDissolve glycine in ddH2O, adjust the pH to 3.0 with HCl, and bring the solution to the final volume. Prepare fresh immediately before use and discard after use. GST storage bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.5)50 mM100 mL2 M NaCl solution150 mM150 mL1 M DTT solution1 mM2 mLGlycerol10 %200 mLddH2ON/Aup to 2LTotalN/A2 LPrepare the buffer just before. Keep at 4°C during use and discard any unused buffer after the experiment. Storage bufferReagentFinal concentrationAmountPBSN/Aup to 2 LNaN30.05 % (w/v)1 gTotalN/A2 LStore at 4°C for up to 2 months. CRITICAL: NaN3 (Sodium azide) is highly toxic. Handle only in chemical fume hood while wearing a lab coat, face mask and nitrile gloves. Avoid inhalation, skin contact, and dust formation. During dissolution, always add the powder slowly to aqueous buffer. Coupling bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.5)20 mM40 mL2 M NaCl solution100 mM100 mL10 % NP-40 solution0.05 %10 mL1 M DTT solution1 mM2 mL0.5 M EDTA solution0.5 mM2 mLGlycerol10 %200 mL0.1 M PMSF solution0.1 mM2 mLddH2ON/Aup to 2LTotalN/A2 LPrepare the buffer just before. Keep at 4°C during use and discard after the experiment. Coupling buffer Prepare the buffer just before. Keep at 4°C during use and discard after the experiment. Blocking bufferReagentFinal concentrationAmountTris1 M6.057 gddH2ON/Aup to 50 mLTotalN/A50 mLAdjust pH to 7.6. Store at 4°C for up to 2 months. Blocking buffer Adjust pH to 7.6. Store at 4°C for up to 2 months. Washing solutionReagentFinal concentrationAmount2 M NaCl solution1 M50 mLddH2ON/Aup to 100 mLTotalN/A100 mLStore at 20°C–25°C for up to 6 months. Washing solution Store at 20°C–25°C for up to 6 months. Elution solutionReagentFinal concentrationAmountGlycine0.1 M0.375 gddH2ON/Aup to 50 mLTotalN/A50 mLDissolve glycine in ddH2O, adjust the pH to 3.0 with HCl, and bring the solution to the final volume. Prepare fresh immediately before use and discard after use. Elution solution Dissolve glycine in ddH2O, adjust the pH to 3.0 with HCl, and bring the solution to the final volume. Prepare fresh immediately before use and discard after use. GST storage bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.5)50 mM100 mL2 M NaCl solution150 mM150 mL1 M DTT solution1 mM2 mLGlycerol10 %200 mLddH2ON/Aup to 2LTotalN/A2 LPrepare the buffer just before. Keep at 4°C during use and discard any unused buffer after the experiment. GST storage buffer Prepare the buffer just before. Keep at 4°C during use and discard any unused buffer after the experiment. Storage bufferReagentFinal concentrationAmountPBSN/Aup to 2 LNaN30.05 % (w/v)1 gTotalN/A2 LStore at 4°C for up to 2 months. Storage buffer Store at 4°C for up to 2 months. CRITICAL: NaN3 (Sodium azide) is highly toxic. Handle only in chemical fume hood while wearing a lab coat, face mask and nitrile gloves. Avoid inhalation, skin contact, and dust formation. During dissolution, always add the powder slowly to aqueous buffer. Reagents for cell fractionation assay Semi-permeabilization bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.4)50 mM2.5 mL2 M KOAc solution110 mM2.75 mL1 M MgCl2 solution2 mM100 μL1 M Benzamidine hydrochloride solution1 mM50 μL5% Digitonin solution0.01%100 μL25× protease inhibitor cocktail solution1×2 mLddH2ON/Aup to 50 mLTotalN/A50 mLPrepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. IP bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.4)50 mM2.5 mL2 M NaCl solution150 mM3.75 mL10% Triton X-100 solution1%5 mL25× protease inhibitor cocktail solution1×2 mLddH2ON/Aup to 50 mLTotalN/A50 mLPrepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. IP-washing bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.4)50 mM2.5 mL2 M NaCl solution150 mM3.75 mL10 % Triton X-100 solution0.5 %2.5 mL25× protease inhibitor cocktail solution1×2 mLddH2ON/Aup to 50 mLTotalN/A50 mLPrepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. 4× SDS sample bufferReagentFinal concentrationAmount2 M Tris-HCl buffer (pH 6.8)200 mM1 mLGlycerol40 % (v/v)4 mLSDS8 % (w/v)0.8 gBromophenol blue0.1 % (w/v)0.01 g1 M DTT solution400 mM4 mLddH2ON/Aup to 10 mLTotalN/A10 mLStore at −20°C in aliquots for up to 6 months to minimize loss of reducing activity and avoid repeated freeze–thaw cycles. CRITICAL: SDS powder is irritating and corrosive, and inhalation or skin contact must be avoided. Handle all reagents in a chemical fume hood while wearing a lab coat, safety glasses, and nitrile gloves. During SDS dissolution, add the powder slowly to the aqueous buffer with continuous mixing. Ensure complete dissolution at 20°C–25°C, as SDS readily precipitates at lower temperatures. 2× SDS sample bufferReagentFinal concentrationAmount4× SDS sample buffer2×0.5 mLddH2ON/Aup to 1 mLTotalN/A1 mLEnsure all components of 4× SDS sample buffer are fully dissolved before dilution. Prepare the buffer just before use and discard after use. Semi-permeabilization bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.4)50 mM2.5 mL2 M KOAc solution110 mM2.75 mL1 M MgCl2 solution2 mM100 μL1 M Benzamidine hydrochloride solution1 mM50 μL5% Digitonin solution0.01%100 μL25× protease inhibitor cocktail solution1×2 mLddH2ON/Aup to 50 mLTotalN/A50 mLPrepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. Semi-permeabilization buffer Prepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. IP bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.4)50 mM2.5 mL2 M NaCl solution150 mM3.75 mL10% Triton X-100 solution1%5 mL25× protease inhibitor cocktail solution1×2 mLddH2ON/Aup to 50 mLTotalN/A50 mLPrepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. IP buffer Prepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. IP-washing bufferReagentFinal concentrationAmount1 M HEPES buffer (pH 7.4)50 mM2.5 mL2 M NaCl solution150 mM3.75 mL10 % Triton X-100 solution0.5 %2.5 mL25× protease inhibitor cocktail solution1×2 mLddH2ON/Aup to 50 mLTotalN/A50 mLPrepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. IP-washing buffer Prepare the buffer immediately before use. Keep the buffer on ice at 4°C during use and discard after the experiment. 4× SDS sample bufferReagentFinal concentrationAmount2 M Tris-HCl buffer (pH 6.8)200 mM1 mLGlycerol40 % (v/v)4 mLSDS8 % (w/v)0.8 gBromophenol blue0.1 % (w/v)0.01 g1 M DTT solution400 mM4 mLddH2ON/Aup to 10 mLTotalN/A10 mLStore at −20°C in aliquots for up to 6 months to minimize loss of reducing activity and avoid repeated freeze–thaw cycles. 4× SDS sample buffer Store at −20°C in aliquots for up to 6 months to minimize loss of reducing activity and avoid repeated freeze–thaw cycles. CRITICAL: SDS powder is irritating and corrosive, and inhalation or skin contact must be avoided. Handle all reagents in a chemical fume hood while wearing a lab coat, safety glasses, and nitrile gloves. During SDS dissolution, add the powder slowly to the aqueous buffer with continuous mixing. Ensure complete dissolution at 20°C–25°C, as SDS readily precipitates at lower temperatures. 2× SDS sample bufferReagentFinal concentrationAmount4× SDS sample buffer2×0.5 mLddH2ON/Aup to 1 mLTotalN/A1 mLEnsure all components of 4× SDS sample buffer are fully dissolved before dilution. Prepare the buffer just before use and discard after use. 2× SDS sample buffer Ensure all components of 4× SDS sample buffer are fully dissolved before dilution. Prepare the buffer just before use and discard after use. Step-by-step method details Cytosol-organelle fractionation Timing: 1–2 h Timing: 1–2 h This method describes cytosol–organelle fractionation in HEK293T cells expressing POMCha and in N43/5 cells for analysis of endogenous POMC (Figure 2A). Perform all steps at 4°C and use freshly harvested cell pellets from the preceding step. Digitonin at low concentration selectively permeabilizes the plasma membrane while leaving the ER and other membrane-bound organelles intact. The released supernatant is collected as the cytosolic fraction.1.Collect the cytosolic fraction.a.Resuspend the cell pellet in ice-cold semi-permeabilization buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by gentle pipetting to break up clumps.b.Incubate the cell suspension for 5 min on ice (see troubleshooting 4 and 5).Note: The volume of semi-permeabilization buffer and incubation time may be adjusted depending on the cell type and experimental conditions.CRITICAL: Avoid vortexing. Excessive agitation or prolonged incubation on ice (>5 min) can compromise fraction integrity.c.Centrifuge at 500 × g for 10 min at 4°C.d.Carefully transfer the supernatant to a pre-chilled tube as the cytosolic fraction.e.Gently resuspend the pellet in 0.5 mL of ice-cold PBS to remove residual digitonin.f.Centrifuge at 500 × g for 5 min at 4°C.g.Discard the supernatant.CRITICAL: Do not disturb the cell pellet.2.Collect the organelle fraction.a.Resuspend the washed pellet in ice-cold IP buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by pipetting and incubate for 10 min on ice (see troubleshooting 4 and 5).Note: Pipette thoroughly to prevent cell clumping.b.Centrifuge at 12,000 × g for 10 min at 4°C.c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the organelle fraction.3.Preparation of whole-cell lysate (input).a.Using the reserved input aliquot (step 8f of before you begin), add 100 μL of RIPA buffer supplemented with 1× protease inhibitor cocktail, and incubate for 20 min on ice with occasional gentle mixing (see troubleshooting 5).b.Centrifuge at 13,500 × g for 15 min at 4°C.c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the whole-cell lysate (input) sample.d.Measure the protein concentration in each fraction using a BCA protein assay kit (Thermo Fisher Scientific, 23227).e.Mix the whole-cell lysate (input for HEK293T cells) and each fraction (for N43/5 cells) separately with 4× SDS sample buffer to obtain a final 1× concentration.f.Adjust the final protein concentration to 1–2 μg/μL.g.Heat at 95°C for 5 min (or according to your immunoblot conditions). The samples are ready for SDS–PAGE.Pause point: The samples can be stored at −20°C until SDS-PAGE analysis.Figure 2Cytosol–organelle fractionation in N43/5 wild-type and Marchf6-KO cells(A) Schematic illustration of subcellular fractionation workflow in N43/5 wild-type (WT) and Marchf6-KO cells. Digitonin extraction selectively permeabilizes the plasma membrane to isolate the cytosolic fraction, followed by Triton X-100 extraction of the ER fraction. Samples were analyzed by western blotting.(B) Immunoblot of whole-cell lysate (Total), digitonin-extracted cytosolic fraction (Dig.), and Triton X-100–extracted ER fraction (TX-100) from N43/5 wild-type and Marchf6-KO cells. Endogenous POMC was detected in the cytosolic fraction of Marchf6-KO cells. Tubulin, Calreticulin, and Sec61α serve as cytosolic, ER luminal, and ER membrane markers, respectively. 1.Collect the cytosolic fraction.a.Resuspend the cell pellet in ice-cold semi-permeabilization buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by gentle pipetting to break up clumps.b.Incubate the cell suspension for 5 min on ice (see troubleshooting 4 and 5).Note: The volume of semi-permeabilization buffer and incubation time may be adjusted depending on the cell type and experimental conditions.CRITICAL: Avoid vortexing. Excessive agitation or prolonged incubation on ice (>5 min) can compromise fraction integrity.c.Centrifuge at 500 × g for 10 min at 4°C.d.Carefully transfer the supernatant to a pre-chilled tube as the cytosolic fraction.e.Gently resuspend the pellet in 0.5 mL of ice-cold PBS to remove residual digitonin.f.Centrifuge at 500 × g for 5 min at 4°C.g.Discard the supernatant.CRITICAL: Do not disturb the cell pellet. Collect the cytosolic fraction.a.Resuspend the cell pellet in ice-cold semi-permeabilization buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by gentle pipetting to break up clumps.b.Incubate the cell suspension for 5 min on ice (see troubleshooting 4 and 5).Note: The volume of semi-permeabilization buffer and incubation time may be adjusted depending on the cell type and experimental conditions.CRITICAL: Avoid vortexing. Excessive agitation or prolonged incubation on ice (>5 min) can compromise fraction integrity.c.Centrifuge at 500 × g for 10 min at 4°C.d.Carefully transfer the supernatant to a pre-chilled tube as the cytosolic fraction.e.Gently resuspend the pellet in 0.5 mL of ice-cold PBS to remove residual digitonin.f.Centrifuge at 500 × g for 5 min at 4°C.g.Discard the supernatant.CRITICAL: Do not disturb the cell pellet. a.Resuspend the cell pellet in ice-cold semi-permeabilization buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by gentle pipetting to break up clumps. Resuspend the cell pellet in ice-cold semi-permeabilization buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by gentle pipetting to break up clumps. b.Incubate the cell suspension for 5 min on ice (see troubleshooting 4 and 5).Note: The volume of semi-permeabilization buffer and incubation time may be adjusted depending on the cell type and experimental conditions.CRITICAL: Avoid vortexing. Excessive agitation or prolonged incubation on ice (>5 min) can compromise fraction integrity. Incubate the cell suspension for 5 min on ice (see troubleshooting 4 and 5).Note: The volume of semi-permeabilization buffer and incubation time may be adjusted depending on the cell type and experimental conditions.CRITICAL: Avoid vortexing. Excessive agitation or prolonged incubation on ice (>5 min) can compromise fraction integrity. Note: The volume of semi-permeabilization buffer and incubation time may be adjusted depending on the cell type and experimental conditions. CRITICAL: Avoid vortexing. Excessive agitation or prolonged incubation on ice (>5 min) can compromise fraction integrity. c.Centrifuge at 500 × g for 10 min at 4°C. Centrifuge at 500 × g for 10 min at 4°C. d.Carefully transfer the supernatant to a pre-chilled tube as the cytosolic fraction. Carefully transfer the supernatant to a pre-chilled tube as the cytosolic fraction. e.Gently resuspend the pellet in 0.5 mL of ice-cold PBS to remove residual digitonin. Gently resuspend the pellet in 0.5 mL of ice-cold PBS to remove residual digitonin. f.Centrifuge at 500 × g for 5 min at 4°C. Centrifuge at 500 × g for 5 min at 4°C. g.Discard the supernatant.CRITICAL: Do not disturb the cell pellet. Discard the supernatant.CRITICAL: Do not disturb the cell pellet. CRITICAL: Do not disturb the cell pellet. 2.Collect the organelle fraction.a.Resuspend the washed pellet in ice-cold IP buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by pipetting and incubate for 10 min on ice (see troubleshooting 4 and 5).Note: Pipette thoroughly to prevent cell clumping.b.Centrifuge at 12,000 × g for 10 min at 4°C.c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the organelle fraction. Collect the organelle fraction.a.Resuspend the washed pellet in ice-cold IP buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by pipetting and incubate for 10 min on ice (see troubleshooting 4 and 5).Note: Pipette thoroughly to prevent cell clumping.b.Centrifuge at 12,000 × g for 10 min at 4°C.c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the organelle fraction. a.Resuspend the washed pellet in ice-cold IP buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by pipetting and incubate for 10 min on ice (see troubleshooting 4 and 5).Note: Pipette thoroughly to prevent cell clumping. Resuspend the washed pellet in ice-cold IP buffer (0.5 mL for N43/5 cells or 1 mL for HEK293T cells) by pipetting and incubate for 10 min on ice (see troubleshooting 4 and 5).Note: Pipette thoroughly to prevent cell clumping. Note: Pipette thoroughly to prevent cell clumping. b.Centrifuge at 12,000 × g for 10 min at 4°C. Centrifuge at 12,000 × g for 10 min at 4°C. c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the organelle fraction. Transfer the supernatant to a pre-chilled microcentrifuge tube as the organelle fraction. 3.Preparation of whole-cell lysate (input).a.Using the reserved input aliquot (step 8f of before you begin), add 100 μL of RIPA buffer supplemented with 1× protease inhibitor cocktail, and incubate for 20 min on ice with occasional gentle mixing (see troubleshooting 5).b.Centrifuge at 13,500 × g for 15 min at 4°C.c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the whole-cell lysate (input) sample.d.Measure the protein concentration in each fraction using a BCA protein assay kit (Thermo Fisher Scientific, 23227).e.Mix the whole-cell lysate (input for HEK293T cells) and each fraction (for N43/5 cells) separately with 4× SDS sample buffer to obtain a final 1× concentration.f.Adjust the final protein concentration to 1–2 μg/μL.g.Heat at 95°C for 5 min (or according to your immunoblot conditions). The samples are ready for SDS–PAGE. Preparation of whole-cell lysate (input).a.Using the reserved input aliquot (step 8f of before you begin), add 100 μL of RIPA buffer supplemented with 1× protease inhibitor cocktail, and incubate for 20 min on ice with occasional gentle mixing (see troubleshooting 5).b.Centrifuge at 13,500 × g for 15 min at 4°C.c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the whole-cell lysate (input) sample.d.Measure the protein concentration in each fraction using a BCA protein assay kit (Thermo Fisher Scientific, 23227).e.Mix the whole-cell lysate (input for HEK293T cells) and each fraction (for N43/5 cells) separately with 4× SDS sample buffer to obtain a final 1× concentration.f.Adjust the final protein concentration to 1–2 μg/μL.g.Heat at 95°C for 5 min (or according to your immunoblot conditions). The samples are ready for SDS–PAGE. a.Using the reserved input aliquot (step 8f of before you begin), add 100 μL of RIPA buffer supplemented with 1× protease inhibitor cocktail, and incubate for 20 min on ice with occasional gentle mixing (see troubleshooting 5). Using the reserved input aliquot (step 8f of before you begin), add 100 μL of RIPA buffer supplemented with 1× protease inhibitor cocktail, and incubate for 20 min on ice with occasional gentle mixing (see troubleshooting 5). b.Centrifuge at 13,500 × g for 15 min at 4°C. Centrifuge at 13,500 × g for 15 min at 4°C. c.Transfer the supernatant to a pre-chilled microcentrifuge tube as the whole-cell lysate (input) sample. Transfer the supernatant to a pre-chilled microcentrifuge tube as the whole-cell lysate (input) sample. d.Measure the protein concentration in each fraction using a BCA protein assay kit (Thermo Fisher Scientific, 23227). Measure the protein concentration in each fraction using a BCA protein assay kit (Thermo Fisher Scientific, 23227). e.Mix the whole-cell lysate (input for HEK293T cells) and each fraction (for N43/5 cells) separately with 4× SDS sample buffer to obtain a final 1× concentration. Mix the whole-cell lysate (input for HEK293T cells) and each fraction (for N43/5 cells) separately with 4× SDS sample buffer to obtain a final 1× concentration. f.Adjust the final protein concentration to 1–2 μg/μL. Adjust the final protein concentration to 1–2 μg/μL. g.Heat at 95°C for 5 min (or according to your immunoblot conditions). The samples are ready for SDS–PAGE. Heat at 95°C for 5 min (or according to your immunoblot conditions). The samples are ready for SDS–PAGE. Pause point: The samples can be stored at −20°C until SDS-PAGE analysis. Cytosol–organelle fractionation in N43/5 wild-type and Marchf6-KO cells (A) Schematic illustration of subcellular fractionation workflow in N43/5 wild-type (WT) and Marchf6-KO cells. Digitonin extraction selectively permeabilizes the plasma membrane to isolate the cytosolic fraction, followed by Triton X-100 extraction of the ER fraction. Samples were analyzed by western blotting. (B) Immunoblot of whole-cell lysate (Total), digitonin-extracted cytosolic fraction (Dig.), and Triton X-100–extracted ER fraction (TX-100) from N43/5 wild-type and Marchf6-KO cells. Endogenous POMC was detected in the cytosolic fraction of Marchf6-KO cells. Tubulin, Calreticulin, and Sec61α serve as cytosolic, ER luminal, and ER membrane markers, respectively. Co-immunoprecipitation with anti-POMCSP Timing: 4 days total; 2 days for steps 4–6; 2 days for step 7 Timing: 4 days total; 2 days for steps 4–6; 2 days for step 7 This protocol describes co-immunoprecipitation (co-IP) using anti-POMCSP antibody from cytosolic and organelle fractions of HEK293T cells expressing POMCha (Figure 3A). Before starting, pre-chill all reagents, tubes, and the centrifuge to 4°C.4.Incubation of subcellular fractions with anti-POMCSP antibody (Figure 3A).a.Measure the protein concentration in each fraction using a BCA protein assay kit.b.Normalize 1 mg of cytosolic and organelle fractions to the same final volume using the corresponding buffer.Note: For example, if 1 mg of cytosolic fraction from vehicle–treated and EerI–treated samples yields volumes of 850 μL and 900 μL, respectively, adjust all samples to 900 μL with the corresponding buffer.c.Add 5 μg of anti-POMCSP antibody to each sample and incubate on an orbital rotator for 12–16 h at 4°C (see troubleshooting 3 and 6).Note: Use of 5 μg anti-POMCSP per mg of lysate, as determined by antibody validation (Figure 1C). For newly prepared anti-POMCSP batches or different cell types, titrate the antibody amount before immunoprecipitation.5.Preparation of Dynabeads Protein G.a.Resuspend Dynabeads Protein G thoroughly.b.Transfer the 120 μg (4 μL) of beads into a pre-chilled microcentrifuge tube.c.Add 0.5 mL of appropriate buffer (semi-permeabilization buffer or IP buffer) to the beads.d.Equilibrate the beads in 0.5 mL of the same buffer for 5–10 min at 4°C with rotation.e.Place the tube on a magnetic rack and discard the supernatant. Repeat steps 5c and 5d once more.6.Immunoprecipitate POMCha including signal peptide.a.Add the antibody-incubated fraction (from step 4c) directly to the washed Dynabeads and incubate on an orbital rotator for 1.5 h at 4°C.b.Wash with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation (see troubleshooting 6).c.Place the tube on a magnetic rack to separate the beads from the buffer and carefully aspirate the supernatant. Repeat steps 6b and 6c two additional times (see troubleshooting 6).d.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.e.Mix thoroughly and incubate at 95°C for 5 min.f.Place the tube on the magnetic rack again and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples.Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis.7.Immunoblotting to detect cytosolic POMC.Note: This step describes immunoblot analysis of input and immunoprecipitated samples from HEK293T cells expressing POMCha and N43/5 cells for detection of endogenous POMC.a.Load 10 μg of input (corresponding to 5–10 μL) and 5 μL of IP samples onto 10% SDS-PAGE gels and resolve proteins at a constant 80 V for 2.5 h.i.For detection of endogenous POMC in N43/5 cells, load 10 μg of whole-cell lysates and each fractionated sample (typically 5–10 μL).b.Pre-wet PVDF membrane in methanol for 1 min before equilibration in transfer buffer.c.Equilibrate the gels and PVDF membranes in transfer buffer for 3 min.d.Transfer proteins to PVDF membranes at 180 mA for 2.5 h at 4°C.Note: Surround the transfer tank with ice to prevent overheating during transfer.e.Wash the membranes once with PBS-T for 5 min on the shaker with gentle shaking.f.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.g.Wash the membranes once with PBS-T for 5 min on the shaker.h.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12–16 h at 4°C with gentle shaking (see troubleshooting 3).i.Wash the membranes three times with PBS-T for 10 min each on the shaker.j.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C with gentle shaking.k.Wash the membranes three times with PBS-T for 5 min each on the shaker.l.Develop the membranes using a chemiluminescent substrate and capture images using an imaging system (Amersham Imager 680).Note: If signal intensity is low, use a highly sensitive chemiluminescent substrate (e.g., Clarity Max Western ECL substrate, Bio-Rad).Figure 3Cytosolic retention of POMCha upon ER translocation inhibition(A) Schematic overview of the experimental workflow. HEK293T cells expressing POMCha were treated with or without EerI. Cells were fractionated using digitonin to isolate the cytosolic fraction and Triton X-100 to extract the ER fraction. Cytosolic and ER extracts were subjected to co-immunoprecipitation with anti-POMCSP antibody, followed by immunoblotting with anti-ha antibody.(B) Immunoprecipitation with anti-POMCSP followed by anti-ha immunoblot of input, cytosolic (Dig.), and ER (TX-100) fractions from HEK293T cells expressing POMCha ± EerI. Cytosolic SP-uncleaved POMCha was detected upon EerI treatment. Tubulin, Calreticulin, and Sec61α were used as cytosolic, ER luminal, and ER membrane markers, respectively. 4.Incubation of subcellular fractions with anti-POMCSP antibody (Figure 3A).a.Measure the protein concentration in each fraction using a BCA protein assay kit.b.Normalize 1 mg of cytosolic and organelle fractions to the same final volume using the corresponding buffer.Note: For example, if 1 mg of cytosolic fraction from vehicle–treated and EerI–treated samples yields volumes of 850 μL and 900 μL, respectively, adjust all samples to 900 μL with the corresponding buffer.c.Add 5 μg of anti-POMCSP antibody to each sample and incubate on an orbital rotator for 12–16 h at 4°C (see troubleshooting 3 and 6).Note: Use of 5 μg anti-POMCSP per mg of lysate, as determined by antibody validation (Figure 1C). For newly prepared anti-POMCSP batches or different cell types, titrate the antibody amount before immunoprecipitation. Incubation of subcellular fractions with anti-POMCSP antibody (Figure 3A).a.Measure the protein concentration in each fraction using a BCA protein assay kit.b.Normalize 1 mg of cytosolic and organelle fractions to the same final volume using the corresponding buffer.Note: For example, if 1 mg of cytosolic fraction from vehicle–treated and EerI–treated samples yields volumes of 850 μL and 900 μL, respectively, adjust all samples to 900 μL with the corresponding buffer.c.Add 5 μg of anti-POMCSP antibody to each sample and incubate on an orbital rotator for 12–16 h at 4°C (see troubleshooting 3 and 6).Note: Use of 5 μg anti-POMCSP per mg of lysate, as determined by antibody validation (Figure 1C). For newly prepared anti-POMCSP batches or different cell types, titrate the antibody amount before immunoprecipitation. a.Measure the protein concentration in each fraction using a BCA protein assay kit. Measure the protein concentration in each fraction using a BCA protein assay kit. b.Normalize 1 mg of cytosolic and organelle fractions to the same final volume using the corresponding buffer.Note: For example, if 1 mg of cytosolic fraction from vehicle–treated and EerI–treated samples yields volumes of 850 μL and 900 μL, respectively, adjust all samples to 900 μL with the corresponding buffer. Normalize 1 mg of cytosolic and organelle fractions to the same final volume using the corresponding buffer.Note: For example, if 1 mg of cytosolic fraction from vehicle–treated and EerI–treated samples yields volumes of 850 μL and 900 μL, respectively, adjust all samples to 900 μL with the corresponding buffer. Note: For example, if 1 mg of cytosolic fraction from vehicle–treated and EerI–treated samples yields volumes of 850 μL and 900 μL, respectively, adjust all samples to 900 μL with the corresponding buffer. c.Add 5 μg of anti-POMCSP antibody to each sample and incubate on an orbital rotator for 12–16 h at 4°C (see troubleshooting 3 and 6).Note: Use of 5 μg anti-POMCSP per mg of lysate, as determined by antibody validation (Figure 1C). For newly prepared anti-POMCSP batches or different cell types, titrate the antibody amount before immunoprecipitation. Add 5 μg of anti-POMCSP antibody to each sample and incubate on an orbital rotator for 12–16 h at 4°C (see troubleshooting 3 and 6).Note: Use of 5 μg anti-POMCSP per mg of lysate, as determined by antibody validation (Figure 1C). For newly prepared anti-POMCSP batches or different cell types, titrate the antibody amount before immunoprecipitation. Note: Use of 5 μg anti-POMCSP per mg of lysate, as determined by antibody validation (Figure 1C). For newly prepared anti-POMCSP batches or different cell types, titrate the antibody amount before immunoprecipitation. 5.Preparation of Dynabeads Protein G.a.Resuspend Dynabeads Protein G thoroughly.b.Transfer the 120 μg (4 μL) of beads into a pre-chilled microcentrifuge tube.c.Add 0.5 mL of appropriate buffer (semi-permeabilization buffer or IP buffer) to the beads.d.Equilibrate the beads in 0.5 mL of the same buffer for 5–10 min at 4°C with rotation.e.Place the tube on a magnetic rack and discard the supernatant. Repeat steps 5c and 5d once more. Preparation of Dynabeads Protein G.a.Resuspend Dynabeads Protein G thoroughly.b.Transfer the 120 μg (4 μL) of beads into a pre-chilled microcentrifuge tube.c.Add 0.5 mL of appropriate buffer (semi-permeabilization buffer or IP buffer) to the beads.d.Equilibrate the beads in 0.5 mL of the same buffer for 5–10 min at 4°C with rotation.e.Place the tube on a magnetic rack and discard the supernatant. Repeat steps 5c and 5d once more. a.Resuspend Dynabeads Protein G thoroughly. Resuspend Dynabeads Protein G thoroughly. b.Transfer the 120 μg (4 μL) of beads into a pre-chilled microcentrifuge tube. Transfer the 120 μg (4 μL) of beads into a pre-chilled microcentrifuge tube. c.Add 0.5 mL of appropriate buffer (semi-permeabilization buffer or IP buffer) to the beads. Add 0.5 mL of appropriate buffer (semi-permeabilization buffer or IP buffer) to the beads. d.Equilibrate the beads in 0.5 mL of the same buffer for 5–10 min at 4°C with rotation. Equilibrate the beads in 0.5 mL of the same buffer for 5–10 min at 4°C with rotation. e.Place the tube on a magnetic rack and discard the supernatant. Repeat steps 5c and 5d once more. Place the tube on a magnetic rack and discard the supernatant. Repeat steps 5c and 5d once more. 6.Immunoprecipitate POMCha including signal peptide.a.Add the antibody-incubated fraction (from step 4c) directly to the washed Dynabeads and incubate on an orbital rotator for 1.5 h at 4°C.b.Wash with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation (see troubleshooting 6).c.Place the tube on a magnetic rack to separate the beads from the buffer and carefully aspirate the supernatant. Repeat steps 6b and 6c two additional times (see troubleshooting 6).d.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.e.Mix thoroughly and incubate at 95°C for 5 min.f.Place the tube on the magnetic rack again and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples. Immunoprecipitate POMCha including signal peptide.a.Add the antibody-incubated fraction (from step 4c) directly to the washed Dynabeads and incubate on an orbital rotator for 1.5 h at 4°C.b.Wash with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation (see troubleshooting 6).c.Place the tube on a magnetic rack to separate the beads from the buffer and carefully aspirate the supernatant. Repeat steps 6b and 6c two additional times (see troubleshooting 6).d.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample.e.Mix thoroughly and incubate at 95°C for 5 min.f.Place the tube on the magnetic rack again and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples. a.Add the antibody-incubated fraction (from step 4c) directly to the washed Dynabeads and incubate on an orbital rotator for 1.5 h at 4°C. Add the antibody-incubated fraction (from step 4c) directly to the washed Dynabeads and incubate on an orbital rotator for 1.5 h at 4°C. b.Wash with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation (see troubleshooting 6). Wash with 0.5 mL of IP-washing buffer for 5 min at 4°C with rotation (see troubleshooting 6). c.Place the tube on a magnetic rack to separate the beads from the buffer and carefully aspirate the supernatant. Repeat steps 6b and 6c two additional times (see troubleshooting 6). Place the tube on a magnetic rack to separate the beads from the buffer and carefully aspirate the supernatant. Repeat steps 6b and 6c two additional times (see troubleshooting 6). d.After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample. After the final wash, remove residual buffer completely and add 20 μL of 2× SDS sample buffer to each sample. e.Mix thoroughly and incubate at 95°C for 5 min. Mix thoroughly and incubate at 95°C for 5 min. f.Place the tube on the magnetic rack again and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples. Place the tube on the magnetic rack again and transfer the eluate to a new microcentrifuge tube. The resulting samples are referred to as IP samples. Pause point: IP samples can be stored at −20°C until SDS-PAGE analysis. 7.Immunoblotting to detect cytosolic POMC.Note: This step describes immunoblot analysis of input and immunoprecipitated samples from HEK293T cells expressing POMCha and N43/5 cells for detection of endogenous POMC.a.Load 10 μg of input (corresponding to 5–10 μL) and 5 μL of IP samples onto 10% SDS-PAGE gels and resolve proteins at a constant 80 V for 2.5 h.i.For detection of endogenous POMC in N43/5 cells, load 10 μg of whole-cell lysates and each fractionated sample (typically 5–10 μL).b.Pre-wet PVDF membrane in methanol for 1 min before equilibration in transfer buffer.c.Equilibrate the gels and PVDF membranes in transfer buffer for 3 min.d.Transfer proteins to PVDF membranes at 180 mA for 2.5 h at 4°C.Note: Surround the transfer tank with ice to prevent overheating during transfer.e.Wash the membranes once with PBS-T for 5 min on the shaker with gentle shaking.f.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.g.Wash the membranes once with PBS-T for 5 min on the shaker.h.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12–16 h at 4°C with gentle shaking (see troubleshooting 3).i.Wash the membranes three times with PBS-T for 10 min each on the shaker.j.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C with gentle shaking.k.Wash the membranes three times with PBS-T for 5 min each on the shaker.l.Develop the membranes using a chemiluminescent substrate and capture images using an imaging system (Amersham Imager 680).Note: If signal intensity is low, use a highly sensitive chemiluminescent substrate (e.g., Clarity Max Western ECL substrate, Bio-Rad). Immunoblotting to detect cytosolic POMC.Note: This step describes immunoblot analysis of input and immunoprecipitated samples from HEK293T cells expressing POMCha and N43/5 cells for detection of endogenous POMC.a.Load 10 μg of input (corresponding to 5–10 μL) and 5 μL of IP samples onto 10% SDS-PAGE gels and resolve proteins at a constant 80 V for 2.5 h.i.For detection of endogenous POMC in N43/5 cells, load 10 μg of whole-cell lysates and each fractionated sample (typically 5–10 μL).b.Pre-wet PVDF membrane in methanol for 1 min before equilibration in transfer buffer.c.Equilibrate the gels and PVDF membranes in transfer buffer for 3 min.d.Transfer proteins to PVDF membranes at 180 mA for 2.5 h at 4°C.Note: Surround the transfer tank with ice to prevent overheating during transfer.e.Wash the membranes once with PBS-T for 5 min on the shaker with gentle shaking.f.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking.g.Wash the membranes once with PBS-T for 5 min on the shaker.h.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12–16 h at 4°C with gentle shaking (see troubleshooting 3).i.Wash the membranes three times with PBS-T for 10 min each on the shaker.j.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C with gentle shaking.k.Wash the membranes three times with PBS-T for 5 min each on the shaker.l.Develop the membranes using a chemiluminescent substrate and capture images using an imaging system (Amersham Imager 680).Note: If signal intensity is low, use a highly sensitive chemiluminescent substrate (e.g., Clarity Max Western ECL substrate, Bio-Rad). Note: This step describes immunoblot analysis of input and immunoprecipitated samples from HEK293T cells expressing POMCha and N43/5 cells for detection of endogenous POMC. a.Load 10 μg of input (corresponding to 5–10 μL) and 5 μL of IP samples onto 10% SDS-PAGE gels and resolve proteins at a constant 80 V for 2.5 h.i.For detection of endogenous POMC in N43/5 cells, load 10 μg of whole-cell lysates and each fractionated sample (typically 5–10 μL). Load 10 μg of input (corresponding to 5–10 μL) and 5 μL of IP samples onto 10% SDS-PAGE gels and resolve proteins at a constant 80 V for 2.5 h.i.For detection of endogenous POMC in N43/5 cells, load 10 μg of whole-cell lysates and each fractionated sample (typically 5–10 μL). i.For detection of endogenous POMC in N43/5 cells, load 10 μg of whole-cell lysates and each fractionated sample (typically 5–10 μL). For detection of endogenous POMC in N43/5 cells, load 10 μg of whole-cell lysates and each fractionated sample (typically 5–10 μL). b.Pre-wet PVDF membrane in methanol for 1 min before equilibration in transfer buffer. Pre-wet PVDF membrane in methanol for 1 min before equilibration in transfer buffer. c.Equilibrate the gels and PVDF membranes in transfer buffer for 3 min. Equilibrate the gels and PVDF membranes in transfer buffer for 3 min. d.Transfer proteins to PVDF membranes at 180 mA for 2.5 h at 4°C.Note: Surround the transfer tank with ice to prevent overheating during transfer. Transfer proteins to PVDF membranes at 180 mA for 2.5 h at 4°C.Note: Surround the transfer tank with ice to prevent overheating during transfer. Note: Surround the transfer tank with ice to prevent overheating during transfer. e.Wash the membranes once with PBS-T for 5 min on the shaker with gentle shaking. Wash the membranes once with PBS-T for 5 min on the shaker with gentle shaking. f.Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking. Block membranes with 5% non-fat milk in PBS-T for 1 h at 20°C–25°C with gentle shaking. g.Wash the membranes once with PBS-T for 5 min on the shaker. Wash the membranes once with PBS-T for 5 min on the shaker. h.Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12–16 h at 4°C with gentle shaking (see troubleshooting 3). Incubate the membranes with primary antibody diluted in 8–10 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 12–16 h at 4°C with gentle shaking (see troubleshooting 3). i.Wash the membranes three times with PBS-T for 10 min each on the shaker. Wash the membranes three times with PBS-T for 10 min each on the shaker. j.Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C with gentle shaking. Incubate the membranes with HRP-conjugated secondary antibody diluted in 9 mL of 5% non-fat milk in PBS-T (refer to Table 2 for the dilutions of antibodies for immunoblotting) for 1 h at 20°C–25°C with gentle shaking. k.Wash the membranes three times with PBS-T for 5 min each on the shaker. Wash the membranes three times with PBS-T for 5 min each on the shaker. l.Develop the membranes using a chemiluminescent substrate and capture images using an imaging system (Amersham Imager 680).Note: If signal intensity is low, use a highly sensitive chemiluminescent substrate (e.g., Clarity Max Western ECL substrate, Bio-Rad). Develop the membranes using a chemiluminescent substrate and capture images using an imaging system (Amersham Imager 680).Note: If signal intensity is low, use a highly sensitive chemiluminescent substrate (e.g., Clarity Max Western ECL substrate, Bio-Rad). Note: If signal intensity is low, use a highly sensitive chemiluminescent substrate (e.g., Clarity Max Western ECL substrate, Bio-Rad). Cytosolic retention of POMCha upon ER translocation inhibition (A) Schematic overview of the experimental workflow. HEK293T cells expressing POMCha were treated with or without EerI. Cells were fractionated using digitonin to isolate the cytosolic fraction and Triton X-100 to extract the ER fraction. Cytosolic and ER extracts were subjected to co-immunoprecipitation with anti-POMCSP antibody, followed by immunoblotting with anti-ha antibody. (B) Immunoprecipitation with anti-POMCSP followed by anti-ha immunoblot of input, cytosolic (Dig.), and ER (TX-100) fractions from HEK293T cells expressing POMCha ± EerI. Cytosolic SP-uncleaved POMCha was detected upon EerI treatment. Tubulin, Calreticulin, and Sec61α were used as cytosolic, ER luminal, and ER membrane markers, respectively. Expected outcomes In the antibody validation experiment, anti-POMCSP is expected to detect SP-containing GST-POMC1–26 and GST-POMC1–76, but not signal peptide-deleted GST-POMC27–76, by immunoblotting (Figure 1B). For the immunoprecipitation validation, POMCha is expected to be enriched by anti-POMCSP, whereas normal rabbit IgG should produce little or no detectable signal (Figure 1C). In the representative validation shown here, 5 μg anti-POMCSP per mg of lysate provides a clear IP signal from POMCha-expressing lysates, supporting its use for cell-based enrichment of SP-uncleaved POMCha. Cytosol–ER fractionation is expected to yield clearly separated cytosolic and ER fractions, as demonstrated by enrichment of compartment-specific marker proteins in each fraction (Figures 2B and 3B). In Marchf6-KO N43/5 hypothalamic cells, endogenous POMC is expected to be detectable in the cytosolic fraction even in the absence of ER translocon inhibition (Figure 2B). Compared with wild-type cells, the cytosolic POMC signal should be increased, consistent with MARCHF6-dependent turnover of cytosol-retained POMC.1 Upon treatment with the ER translocon inhibitor EerI, POMCha is expected to be retained in the cytosol. Under these conditions, cytosolic POMCha corresponding to the signal peptide-containing precursor form should be detectable by immunoprecipitation with the anti-POMCSP antibody (Figure 3B). Limitations This protocol relies on the signal peptide-specific antibody, anti-POMCSP, to selectively enrich SP-uncleaved POMC. Because anti-POMCSP is not commercially available, each newly prepared the antibody batch should be validated before downstream immunoprecipitation. The validation steps, including immunoblotting of GST-POMC fragments and cell-based immunoprecipitation, are intended to assess antibody specificity and enrichment performance. However, differences in antibody titer, background binding, or epitope accessibility may still affect detection sensitivity between antibody batches. This protocol is optimized for HEK293T cells expressing POMCha and for N43/5 cells used to detect endogenous POMC. Application to other cell types, low-abundance endogenous proteins, or other secretory precursors may require optimization of cell number, drug treatment, digitonin concentration, and antibody amount. For POMCha detection, EerI and MG-132 are used to enrich cytosol-retained SP-uncleaved POMCha. Thus, this protocol is primarily intended for detecting the enriched cytosol-retained pool, rather than for quantitatively measuring basal steady-state abundance. Troubleshooting Problem 1 Weak specificity or performance of anti-POMCSP (steps 3b and 3e of before you begin). Potential solution •Repeat negative selection using GST-POMC27–76 conjugated resin, if cross-reactivity with SP-deleted POMC fragments is observed.•Repeat positive selection using GST-POMC1–76 conjugated resin, if anti-POMCSP is weak.•Reduce the amounts of antisera loaded per selection cycle to avoid saturating the affinity resin.•Avoid prolonged storage of antigen-conjugated resin because antigen degradation can reduce antibody selection efficiency. •Repeat negative selection using GST-POMC27–76 conjugated resin, if cross-reactivity with SP-deleted POMC fragments is observed. Repeat negative selection using GST-POMC27–76 conjugated resin, if cross-reactivity with SP-deleted POMC fragments is observed. •Repeat positive selection using GST-POMC1–76 conjugated resin, if anti-POMCSP is weak. Repeat positive selection using GST-POMC1–76 conjugated resin, if anti-POMCSP is weak. •Reduce the amounts of antisera loaded per selection cycle to avoid saturating the affinity resin. Reduce the amounts of antisera loaded per selection cycle to avoid saturating the affinity resin. •Avoid prolonged storage of antigen-conjugated resin because antigen degradation can reduce antibody selection efficiency. Avoid prolonged storage of antigen-conjugated resin because antigen degradation can reduce antibody selection efficiency. Problem 2 Low transfection efficiency (step 7b of before you begin). Potential solution •Regularly check the mycoplasma contamination of cells.•Use cells at around 60%–80% confluence for transfection.•Optimize the DNA:Lipofectamine 2000 ratio.•Increase the transfection incubation time (up to 72 h). •Regularly check the mycoplasma contamination of cells. Regularly check the mycoplasma contamination of cells. •Use cells at around 60%–80% confluence for transfection. Use cells at around 60%–80% confluence for transfection. •Optimize the DNA:Lipofectamine 2000 ratio. Optimize the DNA:Lipofectamine 2000 ratio. •Increase the transfection incubation time (up to 72 h). Increase the transfection incubation time (up to 72 h). Problem 3 Insufficient POMCha signal (step 7b of before you begin and steps 4c and 7h of step-by-step method details). Potential solution •Increase the amount of plasmid DNA for transfection.•Increase the concentration of anti-POMCSP antibody.•Extend the incubation time of anti-POMCSP antibody with the fractionated lysates.•Optimize the primary antibody conditions (e.g., dilution, incubation time, and temperature). •Increase the amount of plasmid DNA for transfection. Increase the amount of plasmid DNA for transfection. •Increase the concentration of anti-POMCSP antibody. Increase the concentration of anti-POMCSP antibody. •Extend the incubation time of anti-POMCSP antibody with the fractionated lysates. Extend the incubation time of anti-POMCSP antibody with the fractionated lysates. •Optimize the primary antibody conditions (e.g., dilution, incubation time, and temperature). Optimize the primary antibody conditions (e.g., dilution, incubation time, and temperature). Problem 4 Inadequate cytosol‒organelle fractionation (step 8b of before you begin and steps 1a and 2a of step-by-step method details). Potential solution •Optimize the digitonin concentration and incubation time.•Keep the extraction time short and consistent across samples.•Keep cells on ice, scrape gently, and avoid vigorous pipetting.•Confirm that the digitonin stock is freshly prepared or fully dissolved. •Optimize the digitonin concentration and incubation time. Optimize the digitonin concentration and incubation time. •Keep the extraction time short and consistent across samples. Keep the extraction time short and consistent across samples. •Keep cells on ice, scrape gently, and avoid vigorous pipetting. Keep cells on ice, scrape gently, and avoid vigorous pipetting. •Confirm that the digitonin stock is freshly prepared or fully dissolved. Confirm that the digitonin stock is freshly prepared or fully dissolved. Problem 5 Smearing or proteolysis of POMCha band (steps 1a, 2a, and 3a of step-by-step method details). Potential solution •Add fresh of 25× protease inhibitor cocktail stock to the lysis and all fractionation buffer immediately before use.•Add phenylmethanesulfonyl fluoride (PMSF) to a final concentration of 1 mM immediately before use.•Keep cells, lysates, and fractions on ice or at 4°C throughout the procedure.•Minimize the time between cell harvest, lysis and fractionation.•Prepare fresh antibodies for immunoblotting. •Add fresh of 25× protease inhibitor cocktail stock to the lysis and all fractionation buffer immediately before use. Add fresh of 25× protease inhibitor cocktail stock to the lysis and all fractionation buffer immediately before use. •Add phenylmethanesulfonyl fluoride (PMSF) to a final concentration of 1 mM immediately before use. Add phenylmethanesulfonyl fluoride (PMSF) to a final concentration of 1 mM immediately before use. •Keep cells, lysates, and fractions on ice or at 4°C throughout the procedure. Keep cells, lysates, and fractions on ice or at 4°C throughout the procedure. •Minimize the time between cell harvest, lysis and fractionation. Minimize the time between cell harvest, lysis and fractionation. •Prepare fresh antibodies for immunoblotting. Prepare fresh antibodies for immunoblotting. Problem 6 High background bands in the IP lane (steps 4c, 6b, and 6c of step-by-step method details). Potential solution •Reduce the amount of anti-POMCSP.•Increase the wash stringency of IP-washing buffer (e.g., increase the salt or Triton X-100 concentration).•Remove residual wash buffer completely before elution. •Reduce the amount of anti-POMCSP. Reduce the amount of anti-POMCSP. •Increase the wash stringency of IP-washing buffer (e.g., increase the salt or Triton X-100 concentration). Increase the wash stringency of IP-washing buffer (e.g., increase the salt or Triton X-100 concentration). •Remove residual wash buffer completely before elution. Remove residual wash buffer completely before elution. Resource availability Lead contact Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Cheol-Sang Hwang (hwangcs@korea.ac.kr). Technical contact Questions about the technical specifics of performing the protocol should be directed to and will be answered by the technical contact, Sang-Hyeon Mun (shmun@korea.ac.kr). Materials availability Materials are available upon reasonable request. The anti-POMCSP antibody is subject to a pending U.S. patent application and is available for academic research use upon reasonable request. Data and code availability This paper does not report original code. Acknowledgments This work was supported by the Basic Science Research Program through the 10.13039/501100003725National Research Foundation of Korea (10.13039/501100003725NRF), funded by the 10.13039/501100002701Ministry of Education (10.13039/501100002701MOE) (RS-2024-00451336 to S.-H.M.), and by the 10.13039/501100014188Ministry of Science and ICT (10.13039/501100014188MSIT) (RS-2020-NR049401 and RS-2025-16652968 to C.-S.H.). Author contributions S.-H.M. and C.-S.H. developed and optimized the methods. S.-H.M. conducted the experiments. S.-H.M. and C.-S.H. wrote and edited the manuscript. C.-S.H. supervised the study. Declaration of interests The anti-POMCSP antibody is subject to a pending U.S. patent application. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work, the authors used ChatGPT (OpenAI) in order to assist with language editing and grammar correction. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.